Assay
Financial-condition grades for SEC filers
Healthcare [top]
371 graded companies. Letters are fifths of this list; lower percentile is stronger.
Composite score of every graded company in the sector, smoothed. Vertical rules are the letter band edges. Dots are the six largest by market equity.
Weaker this year
| Company | Letters | Move |
|---|---|---|
| Nektar Therapeutics (NKTR) Nektar Therapeutics (NKTR) Eweakest fifth; percentile 97.6 Nasdaq · Pharmaceutical Preparations market equity $1.4B; last close $40.77 Warnings: dilution, short runway; 8 of 14 inputs | A to E | +95 |
| Coherus Oncology, Inc. (CHRS) Coherus Oncology, Inc. (CHRS) Eweakest fifth; percentile 98.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $165.3M; last close $1.06 Warnings: dilution, short runway; 10 of 14 inputs | A to E | +90 |
| Co-Diagnostics, Inc. (CODX) Co-Diagnostics, Inc. (CODX) Eweakest fifth; percentile 94.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $6.8M; last close $1.10 Warnings: dilution, short runway, fortress balance sheet; 8 of 14 inputs | A to E | +82 |
| Moderna, Inc. (MRNA) Moderna, Inc. (MRNA) D/Eon the D/E boundary; percentile 82.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $78.6B; last close $197.00 No active warnings; 8 of 14 inputs | A to D/E | +80 |
| SkinHealth Systems Inc. (SKIN) SkinHealth Systems Inc. (SKIN) Eweakest fifth; percentile 83.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $74.0M; last close $0.57 No active warnings; 8 of 14 inputs | A to E | +80 |
Stronger this year
| Company | Letters | Move |
|---|---|---|
| Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) Astrongest fifth; percentile 2.2 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $14.6B; last close $59.01 Warnings: fortress balance sheet; 10 of 14 inputs | E to A | -89 |
| Ardelyx, Inc. (ARDX) Ardelyx, Inc. (ARDX) Astrongest fifth; percentile 13.5 Nasdaq · Pharmaceutical Preparations market equity $814.8M; last close $3.27 No active warnings; 8 of 14 inputs | E to A | -82 |
| LivaNova plc (LIVN) LivaNova plc (LIVN) Astrongest fifth; percentile 10.0 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $4.2B; last close $75.93 Warnings: fortress balance sheet; 10 of 14 inputs | E to A | -74 |
| Avalo Therapeutics, Inc. (AVTX) Avalo Therapeutics, Inc. (AVTX) Bsecond fifth; percentile 23.8 Nasdaq · Pharmaceutical Preparations market equity $720.3M; last close $13.43 Warnings: dilution, degenerate inputs; 7 of 14 inputs | E to B | -72 |
| Boston Scientific Corp. (BSX) Boston Scientific Corp. (BSX) A/Bon the A/B boundary; percentile 20.3 NYSE · Surgical & Medical Instruments & Apparatus market equity $60.9B; last close $42.03 No active warnings; 12 of 14 inputs | E to A/B | -72 |
Every Graded Company
| Rank | Company | Letter | Percentile | Market equity | 12-1 | Warnings |
|---|---|---|---|---|---|---|
| 1 | Protagonist Therapeutics, Inc. (PTGX) Protagonist Therapeutics, Inc. (PTGX) Astrongest fifth; percentile 0.0 Nasdaq · Pharmaceutical Preparations market equity $9.1B; last close $139.91 Warnings: fortress balance sheet; 7 of 14 inputs | A | 0.0 | $9.1B | +122% | fortress balance sheet |
| 2 | Delcath Systems, Inc. (DCTH) Delcath Systems, Inc. (DCTH) Astrongest fifth; percentile 0.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $521.9M; last close $15.04 Warnings: fortress balance sheet; 8 of 14 inputs | A | 0.3 | $521.9M | +53% | fortress balance sheet |
| 3 | Inspire Medical Systems, Inc. (INSP) Inspire Medical Systems, Inc. (INSP) Astrongest fifth; percentile 0.5 NYSE · Surgical & Medical Instruments & Apparatus market equity $1.9B; last close $66.50 Warnings: fortress balance sheet; 10 of 14 inputs | A | 0.5 | $1.9B | -15% | fortress balance sheet |
| 4 | Kiniksa Pharmaceuticals International, plc (KNSA) Kiniksa Pharmaceuticals International, plc (KNSA) Astrongest fifth; percentile 0.8 Nasdaq · Pharmaceutical Preparations last close $78.77 No active warnings; 8 of 14 inputs | A | 0.8 | +102% | ||
| 5 | Mimedx Group, Inc. (MDXG) Mimedx Group, Inc. (MDXG) Astrongest fifth; percentile 1.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $673.4M; last close $4.62 Warnings: fortress balance sheet; 10 of 14 inputs | A | 1.1 | $673.4M | -35% | fortress balance sheet |
| 6 | Harmony Biosciences Holdings, Inc. (HRMY) Harmony Biosciences Holdings, Inc. (HRMY) Astrongest fifth; percentile 1.4 Nasdaq · Pharmaceutical Preparations market equity $2.3B; last close $39.60 Warnings: fortress balance sheet; 11 of 14 inputs | A | 1.4 | $2.3B | +43% | fortress balance sheet |
| 7 | BeOne Medicines Ltd. (ONC) BeOne Medicines Ltd. (ONC) Astrongest fifth; percentile 1.6 Nasdaq · Pharmaceutical Preparations last close $350.00 Warnings: fortress balance sheet; 9 of 14 inputs | A | 1.6 | +6% | fortress balance sheet | |
| 8 | Progyny, Inc. (PGNY) Progyny, Inc. (PGNY) Astrongest fifth; percentile 1.9 Nasdaq · Services-Misc Health & Allied Services, NEC market equity $2.1B; last close $27.84 No active warnings; 10 of 14 inputs | A | 1.9 | $2.1B | +19% | |
| 9 | Exelixis, Inc. (EXEL) Exelixis, Inc. (EXEL) Astrongest fifth; percentile 2.2 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $14.6B; last close $59.01 Warnings: fortress balance sheet; 10 of 14 inputs | A | 2.2 | $14.6B | +32% | fortress balance sheet |
| 10 | Iradimed Corp. (IRMD) Iradimed Corp. (IRMD) Astrongest fifth; percentile 2.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.1B; last close $86.21 No active warnings; 9 of 14 inputs | A | 2.4 | $1.1B | +23% | |
| 11 | Castle Biosciences Inc. (CSTL) Castle Biosciences Inc. (CSTL) Astrongest fifth; percentile 2.7 Nasdaq · Services-Medical Laboratories market equity $1.0B; last close $33.65 Warnings: fortress balance sheet; 9 of 14 inputs | A | 2.7 | $1.0B | +45% | fortress balance sheet |
| 12 | Penumbra Inc. (PEN) Penumbra Inc. (PEN) Astrongest fifth; percentile 3.0 NYSE · Surgical & Medical Instruments & Apparatus market equity $12.5B; last close $317.45 No active warnings; 9 of 14 inputs | A | 3.0 | $12.5B | +28% | |
| 13 | Lemaitre Vascular Inc. (LMAT) Lemaitre Vascular Inc. (LMAT) Astrongest fifth; percentile 3.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.8B; last close $79.70 No active warnings; 11 of 14 inputs | A | 3.2 | $1.8B | -7% | |
| 14 | Corcept Therapeutics Inc. (CORT) Corcept Therapeutics Inc. (CORT) Astrongest fifth; percentile 3.5 Nasdaq · Pharmaceutical Preparations market equity $12.8B; last close $118.66 Warnings: fortress balance sheet; 10 of 14 inputs | A | 3.5 | $12.8B | +36% | fortress balance sheet |
| 15 | Electromed, Inc. (ELMD) Electromed, Inc. (ELMD) Astrongest fifth; percentile 3.8 NYSE · Electromedical & Electrotherapeutic Apparatus market equity $232.6M; last close $27.87 Warnings: fortress balance sheet; 9 of 14 inputs | A | 3.8 | $232.6M | +14% | fortress balance sheet |
| 16 | Tactile Systems Technology Inc. (TCMD) Tactile Systems Technology Inc. (TCMD) Astrongest fifth; percentile 4.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $501.1M; last close $22.11 Warnings: fortress balance sheet; 11 of 14 inputs | A | 4.1 | $501.1M | +66% | fortress balance sheet |
| 17 | Ideaya Biosciences, Inc. (IDYA) Ideaya Biosciences, Inc. (IDYA) Astrongest fifth; percentile 4.3 Nasdaq · Pharmaceutical Preparations market equity $3.5B; last close $36.06 No active warnings; 7 of 14 inputs | A | 4.3 | $3.5B | +47% | |
| 18 | Vericel Corp. (VCEL) Vericel Corp. (VCEL) Astrongest fifth; percentile 4.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.1B; last close $40.02 No active warnings; 11 of 14 inputs | A | 4.6 | $2.1B | +27% | |
| 19 | Tarsus Pharmaceuticals, Inc. (TARS) Tarsus Pharmaceuticals, Inc. (TARS) Astrongest fifth; percentile 4.9 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $3.2B; last close $72.26 Warnings: fortress balance sheet; 7 of 14 inputs | A | 4.9 | $3.2B | +25% | fortress balance sheet |
| 20 | Biomarin Pharmaceutical Inc. (BMRN) Biomarin Pharmaceutical Inc. (BMRN) Astrongest fifth; percentile 5.1 Nasdaq · Pharmaceutical Preparations market equity $10.6B; last close $54.88 No active warnings; 10 of 14 inputs | A | 5.1 | $10.6B | +20% | |
| 21 | Neurocrine Biosciences Inc. (NBIX) Neurocrine Biosciences Inc. (NBIX) Astrongest fifth; percentile 5.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $14.4B; last close $141.26 No active warnings; 9 of 14 inputs | A | 5.4 | $14.4B | +10% | |
| 22 | Crispr Therapeutics AG (CRSP) Crispr Therapeutics AG (CRSP) Astrongest fifth; percentile 5.7 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $4.9B; last close $50.41 No active warnings; 7 of 14 inputs | A | 5.7 | $4.9B | -12% | |
| 23 | SBC Medical Group Holdings Inc. (SBC) SBC Medical Group Holdings Inc. (SBC) Astrongest fifth; percentile 6.1 Nasdaq · Services-Offices & Clinics of Doctors of Medicine last close $5.33 Warnings: fortress balance sheet; 9 of 14 inputs | A | 6.1 | -7% | fortress balance sheet | |
| 24 | SBC Medical Group Holdings Inc. (SBCWW) SBC Medical Group Holdings Inc. (SBCWW) Astrongest fifth; percentile 6.1 Nasdaq · Services-Offices & Clinics of Doctors of Medicine last close $0.28 Warnings: fortress balance sheet; 9 of 14 inputs | A | 6.1 | +36% | fortress balance sheet | |
| 25 | United Therapeutics Corp. (UTHR) United Therapeutics Corp. (UTHR) Astrongest fifth; percentile 6.5 Nasdaq · Pharmaceutical Preparations market equity $22.9B; last close $532.45 No active warnings; 11 of 14 inputs | A | 6.5 | $22.9B | +22% | |
| 26 | AtriCure, Inc. (ATRC) AtriCure, Inc. (ATRC) Astrongest fifth; percentile 6.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $2.7B; last close $52.88 No active warnings; 8 of 14 inputs | A | 6.8 | $2.7B | +37% | |
| 27 | Intuitive Surgical Inc. (ISRG) Intuitive Surgical Inc. (ISRG) Astrongest fifth; percentile 7.0 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $146.8B; last close $415.60 No active warnings; 11 of 14 inputs | A | 7.0 | $146.8B | -16% | |
| 28 | iRhythm Holdings, Inc. (IRTC) iRhythm Holdings, Inc. (IRTC) Astrongest fifth; percentile 7.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $3.4B; last close $102.84 Warnings: fortress balance sheet; 9 of 14 inputs | A | 7.3 | $3.4B | -31% | fortress balance sheet |
| 29 | Globus Medical Inc. (GMED) Globus Medical Inc. (GMED) Astrongest fifth; percentile 7.6 NYSE · Surgical & Medical Instruments & Apparatus market equity $9.8B; last close $73.39 No active warnings; 11 of 14 inputs | A | 7.6 | $9.8B | +42% | |
| 30 | Hims & Hers Health, Inc. (HIMS) Hims & Hers Health, Inc. (HIMS) Astrongest fifth; percentile 7.8 NYSE · Services-Offices & Clinics of Doctors of Medicine last close $28.06 No active warnings; 7 of 14 inputs | A | 7.8 | -48% | ||
| 31 | Gyre Therapeutics, Inc. (GYRE) Gyre Therapeutics, Inc. (GYRE) Astrongest fifth; percentile 8.1 Nasdaq · Pharmaceutical Preparations market equity $753.8M; last close $6.76 Warnings: fortress balance sheet; 8 of 14 inputs | A | 8.1 | $753.8M | -12% | fortress balance sheet |
| 32 | Veracyte, Inc. (VCYT) Veracyte, Inc. (VCYT) Astrongest fifth; percentile 8.4 Nasdaq · Services-Medical Laboratories market equity $3.5B; last close $43.59 No active warnings; 8 of 14 inputs | A | 8.4 | $3.5B | +26% | |
| 33 | Alkermes plc. (ALKS) Alkermes plc. (ALKS) Astrongest fifth; percentile 8.6 Nasdaq · Pharmaceutical Preparations market equity $6.7B; last close $40.11 No active warnings; 9 of 14 inputs | A | 8.6 | $6.7B | +57% | |
| 34 | Si-Bone, Inc. (SIBN) Si-Bone, Inc. (SIBN) Astrongest fifth; percentile 8.9 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $845.3M; last close $18.88 Warnings: fortress balance sheet; 9 of 14 inputs | A | 8.9 | $845.3M | +29% | fortress balance sheet |
| 35 | Viridian Therapeutics, Inc.\DE (VRDN) Viridian Therapeutics, Inc.\DE (VRDN) Astrongest fifth; percentile 9.2 Nasdaq · Pharmaceutical Preparations market equity $2.1B; last close $18.34 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | A | 9.2 | $2.1B | +7% | dilution, fortress balance sheet |
| 36 | Xtant Medical Holdings, Inc. (XTNT) Xtant Medical Holdings, Inc. (XTNT) Astrongest fifth; percentile 9.5 NYSE · Surgical & Medical Instruments & Apparatus market equity $45.0M; last close $0.32 Warnings: fortress balance sheet; 12 of 14 inputs | A | 9.5 | $45.0M | -40% | fortress balance sheet |
| 37 | Viemed Healthcare, Inc. (VMD) Viemed Healthcare, Inc. (VMD) Astrongest fifth; percentile 9.7 Nasdaq · Services-Misc Health & Allied Services, NEC market equity $358.4M; last close $9.41 No active warnings; 10 of 14 inputs | A | 9.7 | $358.4M | +30% | |
| 38 | LivaNova plc (LIVN) LivaNova plc (LIVN) Astrongest fifth; percentile 10.0 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $4.2B; last close $75.93 Warnings: fortress balance sheet; 10 of 14 inputs | A | 10.0 | $4.2B | +52% | fortress balance sheet |
| 39 | TransMedics Group, Inc. (TMDX) TransMedics Group, Inc. (TMDX) Astrongest fifth; percentile 10.3 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $2.7B; last close $78.95 No active warnings; 8 of 14 inputs | A | 10.3 | $2.7B | -24% | |
| 40 | TG Therapeutics, Inc. (TGTX) TG Therapeutics, Inc. (TGTX) Astrongest fifth; percentile 10.5 Nasdaq · Pharmaceutical Preparations market equity $8.2B; last close $53.33 No active warnings; 8 of 14 inputs | A | 10.5 | $8.2B | +50% | |
| 41 | Niagen Bioscience, Inc. (NAGE) Niagen Bioscience, Inc. (NAGE) Astrongest fifth; percentile 10.8 Nasdaq · Medicinal Chemicals & Botanical Products market equity $210.5M; last close $2.65 No active warnings; 8 of 14 inputs | A | 10.8 | $210.5M | -66% | |
| 42 | BridgeBio Pharma, Inc. (BBIO) BridgeBio Pharma, Inc. (BBIO) Astrongest fifth; percentile 11.1 Nasdaq · Pharmaceutical Preparations market equity $12.7B; last close $64.99 No active warnings; 7 of 14 inputs | A | 11.1 | $12.7B | +47% | |
| 43 | PRO DEX Inc. (PDEX) PRO DEX Inc. (PDEX) Astrongest fifth; percentile 11.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $199.3M; last close $61.87 No active warnings; 12 of 14 inputs | A | 11.4 | $199.3M | +83% | |
| 44 | Sanara MedTech Inc. (SMTI) Sanara MedTech Inc. (SMTI) Astrongest fifth; percentile 11.6 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $322.0M; last close $35.02 No active warnings; 10 of 14 inputs | A | 11.6 | $322.0M | +10% | |
| 45 | Orthopediatrics Corp. (KIDS) Orthopediatrics Corp. (KIDS) Astrongest fifth; percentile 11.9 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $568.1M; last close $21.79 No active warnings; 9 of 14 inputs | A | 11.9 | $568.1M | +26% | |
| 46 | Idexx Laboratories Inc. (IDXX) Idexx Laboratories Inc. (IDXX) Astrongest fifth; percentile 12.2 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $40.4B; last close $513.14 No active warnings; 12 of 14 inputs | A | 12.2 | $40.4B | -13% | |
| 47 | Procept BioRobotics Corp. (PRCT) Procept BioRobotics Corp. (PRCT) Astrongest fifth; percentile 12.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.0B; last close $17.91 Warnings: fortress balance sheet; 8 of 14 inputs | A | 12.4 | $1.0B | -41% | fortress balance sheet |
| 48 | Natera, Inc. (NTRA) Natera, Inc. (NTRA) Astrongest fifth; percentile 12.7 Nasdaq · Services-Medical Laboratories market equity $56.3B; last close $390.68 Warnings: fortress balance sheet; 7 of 14 inputs | A | 12.7 | $56.3B | +100% | fortress balance sheet |
| 49 | Utah Medical Products Inc. (UTMD) Utah Medical Products Inc. (UTMD) Astrongest fifth; percentile 13.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $235.2M; last close $73.91 Warnings: fortress balance sheet; 12 of 14 inputs | A | 13.0 | $235.2M | +14% | fortress balance sheet |
| 50 | Insulet Corp. (PODD) Insulet Corp. (PODD) Astrongest fifth; percentile 13.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $9.3B; last close $134.39 No active warnings; 9 of 14 inputs | A | 13.2 | $9.3B | -52% | |
| 51 | Ardelyx, Inc. (ARDX) Ardelyx, Inc. (ARDX) Astrongest fifth; percentile 13.5 Nasdaq · Pharmaceutical Preparations market equity $814.8M; last close $3.27 No active warnings; 8 of 14 inputs | A | 13.5 | $814.8M | -31% | |
| 52 | Resmed Inc. (RMD) Resmed Inc. (RMD) Astrongest fifth; percentile 13.8 NYSE · Surgical & Medical Instruments & Apparatus last close $226.62 Warnings: fortress balance sheet; 11 of 14 inputs | A | 13.8 | -11% | fortress balance sheet | |
| 53 | Janux Therapeutics, Inc. (JANX) Janux Therapeutics, Inc. (JANX) Astrongest fifth; percentile 14.1 Nasdaq · Pharmaceutical Preparations market equity $1.1B; last close $18.50 No active warnings; 7 of 14 inputs | A | 14.1 | $1.1B | -25% | |
| 54 | Treace Medical Concepts, Inc. (TMCI) Treace Medical Concepts, Inc. (TMCI) Astrongest fifth; percentile 14.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $252.0M; last close $3.88 No active warnings; 10 of 14 inputs | A | 14.3 | $252.0M | -30% | |
| 55 | Lantheus Holdings, Inc. (LNTH) Lantheus Holdings, Inc. (LNTH) Astrongest fifth; percentile 14.6 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $6.5B; last close $100.09 No active warnings; 9 of 14 inputs | A | 14.6 | $6.5B | +97% | |
| 56 | Harrow, Inc. (HROW) Harrow, Inc. (HROW) Astrongest fifth; percentile 14.9 Nasdaq · Pharmaceutical Preparations market equity $1.1B; last close $30.59 Warnings: late filer; 8 of 14 inputs | A | 14.9 | $1.1B | -23% | late filer |
| 57 | Edwards Lifesciences Corp. (EW) Edwards Lifesciences Corp. (EW) Astrongest fifth; percentile 15.1 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $48.6B; last close $84.24 No active warnings; 11 of 14 inputs | A | 15.1 | $48.6B | +17% | |
| 58 | Vertex Pharmaceuticals Inc. MA (VRTX) Vertex Pharmaceuticals Inc. MA (VRTX) Astrongest fifth; percentile 15.4 Nasdaq · Pharmaceutical Preparations market equity $127.6B; last close $503.17 No active warnings; 11 of 14 inputs | A | 15.4 | $127.6B | +39% | |
| 59 | CareDx, Inc. (CDNA) CareDx, Inc. (CDNA) Astrongest fifth; percentile 15.7 Nasdaq · Services-Medical Laboratories market equity $3.2B; last close $62.25 No active warnings; 7 of 14 inputs | A | 15.7 | $3.2B | +245% | |
| 60 | Ensign Group, Inc. (ENSG) Ensign Group, Inc. (ENSG) Astrongest fifth; percentile 15.9 Nasdaq · Services-Skilled Nursing Care Facilities market equity $10.0B; last close $171.41 Warnings: fortress balance sheet; 11 of 14 inputs | A | 15.9 | $10.0B | -0% | fortress balance sheet |
| 61 | RxSight, Inc. (RXST) RxSight, Inc. (RXST) Astrongest fifth; percentile 16.2 Nasdaq · Ophthalmic Goods market equity $201.7M; last close $4.86 Warnings: fortress balance sheet; 9 of 14 inputs | A | 16.2 | $201.7M | -18% | fortress balance sheet |
| 62 | Definium Therapeutics, Inc. (DFTX) Definium Therapeutics, Inc. (DFTX) Astrongest fifth; percentile 16.5 Nasdaq · Medicinal Chemicals & Botanical Products market equity $4.6B; last close $34.17 Warnings: dilution; 7 of 14 inputs | A | 16.5 | $4.6B | +237% | dilution |
| 63 | Natures Sunshine Products Inc. (NATR) Natures Sunshine Products Inc. (NATR) Astrongest fifth; percentile 16.8 Nasdaq · Pharmaceutical Preparations market equity $221.2M; last close $12.56 Warnings: fortress balance sheet; 9 of 14 inputs | A | 16.8 | $221.2M | -9% | fortress balance sheet |
| 64 | Alnylam Pharmaceuticals, Inc. (ALNY) Alnylam Pharmaceuticals, Inc. (ALNY) Astrongest fifth; percentile 17.0 Nasdaq · Pharmaceutical Preparations market equity $30.0B; last close $224.51 No active warnings; 9 of 14 inputs | A | 17.0 | $30.0B | -47% | |
| 65 | Aurinia Pharmaceuticals Inc. (AUPH) Aurinia Pharmaceuticals Inc. (AUPH) Astrongest fifth; percentile 17.3 Nasdaq · Pharmaceutical Preparations market equity $2.2B; last close $16.22 No active warnings; 8 of 14 inputs | A | 17.3 | $2.2B | +46% | |
| 66 | Acadia Pharmaceuticals Inc. (ACAD) Acadia Pharmaceuticals Inc. (ACAD) A/Bon the A/B boundary; percentile 17.6 Nasdaq · Pharmaceutical Preparations market equity $3.4B; last close $19.57 No active warnings; 8 of 14 inputs | A/B | 17.6 | $3.4B | +35% | |
| 67 | UFP Technologies Inc. (UFPT) UFP Technologies Inc. (UFPT) A/Bon the A/B boundary; percentile 17.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $2.2B; last close $287.96 No active warnings; 10 of 14 inputs | A/B | 17.8 | $2.2B | +49% | |
| 68 | Conmed Corp. (CNMD) Conmed Corp. (CNMD) A/Bon the A/B boundary; percentile 18.1 NYSE · Electromedical & Electrotherapeutic Apparatus market equity $1.4B; last close $45.19 No active warnings; 11 of 14 inputs | A/B | 18.1 | $1.4B | +6% | |
| 69 | Dexcom Inc. (DXCM) Dexcom Inc. (DXCM) A/Bon the A/B boundary; percentile 18.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $31.9B; last close $84.44 Warnings: fortress balance sheet; 10 of 14 inputs | A/B | 18.4 | $31.9B | +35% | fortress balance sheet |
| 70 | Orthofix Medical Inc. (OFIX) Orthofix Medical Inc. (OFIX) A/Bon the A/B boundary; percentile 18.6 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $366.6M; last close $8.99 No active warnings; 8 of 14 inputs | A/B | 18.6 | $366.6M | -36% | |
| 71 | Adma Biologics, Inc. (ADMA) Adma Biologics, Inc. (ADMA) A/Bon the A/B boundary; percentile 18.9 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.3B; last close $10.32 Warnings: late filer, fortress balance sheet; 10 of 14 inputs | A/B | 18.9 | $2.3B | -36% | late filer, fortress balance sheet |
| 72 | InnovAge Holding Corp. (INNV) InnovAge Holding Corp. (INNV) A/Bon the A/B boundary; percentile 19.2 Nasdaq · Services-Health Services market equity $1.2B; last close $9.11 Warnings: fortress balance sheet; 9 of 14 inputs | A/B | 19.2 | $1.2B | +109% | fortress balance sheet |
| 73 | Merit Medical Systems Inc. (MMSI) Merit Medical Systems Inc. (MMSI) A/Bon the A/B boundary; percentile 19.5 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $5.1B; last close $85.21 No active warnings; 12 of 14 inputs | A/B | 19.5 | $5.1B | +9% | |
| 74 | Alpha PRO Tech Ltd. (APT) Alpha PRO Tech Ltd. (APT) A/Bon the A/B boundary; percentile 19.7 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $61.2M; last close $5.96 No active warnings; 9 of 14 inputs | A/B | 19.7 | $61.2M | +15% | |
| 75 | Ocular Therapeutix, Inc. (OCUL) Ocular Therapeutix, Inc. (OCUL) A/Bon the A/B boundary; percentile 20.0 Nasdaq · Pharmaceutical Preparations market equity $1.6B; last close $7.51 Warnings: dilution; 8 of 14 inputs | A/B | 20.0 | $1.6B | -10% | dilution |
| 76 | Boston Scientific Corp. (BSX) Boston Scientific Corp. (BSX) A/Bon the A/B boundary; percentile 20.3 NYSE · Surgical & Medical Instruments & Apparatus market equity $60.9B; last close $42.03 No active warnings; 12 of 14 inputs | A/B | 20.3 | $60.9B | -51% | |
| 77 | Siga Technologies Inc. (SIGA) Siga Technologies Inc. (SIGA) A/Bon the A/B boundary; percentile 20.5 Nasdaq · Pharmaceutical Preparations market equity $235.7M; last close $3.27 Warnings: fortress balance sheet; 8 of 14 inputs | A/B | 20.5 | $235.7M | -61% | fortress balance sheet |
| 78 | West Pharmaceutical Services Inc. (WST) West Pharmaceutical Services Inc. (WST) A/Bon the A/B boundary; percentile 20.8 NYSE · Surgical & Medical Instruments & Apparatus market equity $25.6B; last close $363.17 Warnings: fortress balance sheet; 12 of 14 inputs | A/B | 20.8 | $25.6B | +30% | fortress balance sheet |
| 79 | Rigel Pharmaceuticals Inc. (RIGL) Rigel Pharmaceuticals Inc. (RIGL) A/Bon the A/B boundary; percentile 21.1 Nasdaq · Pharmaceutical Preparations market equity $910.1M; last close $48.69 No active warnings; 10 of 14 inputs | A/B | 21.1 | $910.1M | +63% | |
| 80 | Axsome Therapeutics, Inc. (AXSM) Axsome Therapeutics, Inc. (AXSM) A/Bon the A/B boundary; percentile 21.4 Nasdaq · Pharmaceutical Preparations market equity $8.9B; last close $170.26 No active warnings; 7 of 14 inputs | A/B | 21.4 | $8.9B | +63% | |
| 81 | Axogen, Inc. (AXGN) Axogen, Inc. (AXGN) A/Bon the A/B boundary; percentile 21.6 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $1.9B; last close $36.19 No active warnings; 9 of 14 inputs | A/B | 21.6 | $1.9B | +185% | |
| 82 | Halozyme Therapeutics, Inc. (HALO) Halozyme Therapeutics, Inc. (HALO) A/Bon the A/B boundary; percentile 21.9 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $12.5B; last close $109.91 No active warnings; 12 of 14 inputs | A/B | 21.9 | $12.5B | +45% | |
| 83 | 4D Molecular Therapeutics, Inc. (FDMT) 4D Molecular Therapeutics, Inc. (FDMT) A/Bon the A/B boundary; percentile 22.2 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $701.2M; last close $12.71 Warnings: dilution, short runway; 7 of 14 inputs | A/B | 22.2 | $701.2M | +62% | dilution, short runway |
| 84 | Rhythm Pharmaceuticals, Inc. (RYTM) Rhythm Pharmaceuticals, Inc. (RYTM) A/Bon the A/B boundary; percentile 22.4 Nasdaq · Pharmaceutical Preparations market equity $6.2B; last close $89.61 No active warnings; 9 of 14 inputs | A/B | 22.4 | $6.2B | +5% | |
| 85 | Puma Biotechnology, Inc. (PBYI) Puma Biotechnology, Inc. (PBYI) Bsecond fifth; percentile 22.7 Nasdaq · Pharmaceutical Preparations market equity $514.7M; last close $9.99 Warnings: fortress balance sheet; 12 of 14 inputs | B | 22.7 | $514.7M | +72% | fortress balance sheet |
| 86 | Warby Parker Inc. (WRBY) Warby Parker Inc. (WRBY) Bsecond fifth; percentile 23.0 NYSE · Ophthalmic Goods market equity $2.8B; last close $24.96 No active warnings; 7 of 14 inputs | B | 23.0 | $2.8B | -11% | |
| 87 | Cronos Group Inc. (CRON) Cronos Group Inc. (CRON) Bsecond fifth; percentile 23.2 Nasdaq · Medicinal Chemicals & Botanical Products market equity $1.2B; last close $3.23 No active warnings; 9 of 14 inputs | B | 23.2 | $1.2B | +21% | |
| 88 | Guardant Health, Inc. (GH) Guardant Health, Inc. (GH) Bsecond fifth; percentile 23.5 Nasdaq · Services-Medical Laboratories market equity $22.2B; last close $165.62 No active warnings; 7 of 14 inputs | B | 23.5 | $22.2B | +155% | |
| 89 | Avalo Therapeutics, Inc. (AVTX) Avalo Therapeutics, Inc. (AVTX) Bsecond fifth; percentile 23.8 Nasdaq · Pharmaceutical Preparations market equity $720.3M; last close $13.43 Warnings: dilution, degenerate inputs; 7 of 14 inputs | B | 23.8 | $720.3M | +52% | dilution, degenerate inputs |
| 90 | Sarepta Therapeutics, Inc. (SRPT) Sarepta Therapeutics, Inc. (SRPT) Bsecond fifth; percentile 24.1 Nasdaq · Pharmaceutical Preparations market equity $1.9B; last close $18.22 No active warnings; 9 of 14 inputs | B | 24.1 | $1.9B | +9% | |
| 91 | Pulmonx Corp. (LUNG) Pulmonx Corp. (LUNG) Bsecond fifth; percentile 24.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $77.7M; last close $1.80 Warnings: fortress balance sheet; 8 of 14 inputs | B | 24.3 | $77.7M | +47% | fortress balance sheet |
| 92 | Amphastar Pharmaceuticals, Inc. (AMPH) Amphastar Pharmaceuticals, Inc. (AMPH) Bsecond fifth; percentile 24.6 Nasdaq · Pharmaceutical Preparations market equity $1.1B; last close $25.84 No active warnings; 13 of 14 inputs | B | 24.6 | $1.1B | -15% | |
| 93 | Mannatech Inc. (MTEX) Mannatech Inc. (MTEX) Bsecond fifth; percentile 24.9 Nasdaq · Medicinal Chemicals & Botanical Products market equity $15.2M; last close $7.79 Warnings: late filer, fortress balance sheet; 9 of 14 inputs | B | 24.9 | $15.2M | -28% | late filer, fortress balance sheet |
| 94 | NeuroPace Inc. (NPCE) NeuroPace Inc. (NPCE) Bsecond fifth; percentile 25.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $425.3M; last close $12.39 No active warnings; 9 of 14 inputs | B | 25.1 | $425.3M | +42% | |
| 95 | Zoetis Inc. (ZTS) Zoetis Inc. (ZTS) Bsecond fifth; percentile 25.4 NYSE · Pharmaceutical Preparations market equity $30.2B; last close $73.10 No active warnings; 9 of 14 inputs | B | 25.4 | $30.2B | -46% | |
| 96 | Mirum Pharmaceuticals, Inc. (MIRM) Mirum Pharmaceuticals, Inc. (MIRM) Bsecond fifth; percentile 25.7 Nasdaq · Pharmaceutical Preparations market equity $5.3B; last close $81.33 No active warnings; 7 of 14 inputs | B | 25.7 | $5.3B | +34% | |
| 97 | Phibro Animal Health Corp. (PAHC) Phibro Animal Health Corp. (PAHC) Bsecond fifth; percentile 25.9 Nasdaq · Pharmaceutical Preparations last close $37.32 No active warnings; 8 of 14 inputs | B | 25.9 | -6% | ||
| 98 | GE HealthCare Technologies Inc. (GEHC) GE HealthCare Technologies Inc. (GEHC) Bsecond fifth; percentile 26.2 Nasdaq · X-Ray Apparatus & Tubes & Related Irradiation Apparatus market equity $29.2B; last close $64.23 No active warnings; 9 of 14 inputs | B | 26.2 | $29.2B | -5% | |
| 99 | Sensus Healthcare, Inc. (SRTS) Sensus Healthcare, Inc. (SRTS) Bsecond fifth; percentile 26.5 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $48.9M; last close $2.97 No active warnings; 8 of 14 inputs | B | 26.5 | $48.9M | +13% | |
| 100 | Lineage Cell Therapeutics, Inc. (LCTX) Lineage Cell Therapeutics, Inc. (LCTX) Bsecond fifth; percentile 26.8 NYSE · Biological Products, (No Diagnostic Substances) market equity $260.5M; last close $1.02 No active warnings; 7 of 14 inputs | B | 26.8 | $260.5M | -35% | |
| 101 | Travere Therapeutics, Inc. (TVTX) Travere Therapeutics, Inc. (TVTX) Bsecond fifth; percentile 27.0 Nasdaq · Pharmaceutical Preparations market equity $4.9B; last close $52.05 No active warnings; 8 of 14 inputs | B | 27.0 | $4.9B | +177% | |
| 102 | Tela Bio, Inc. (TELA) Tela Bio, Inc. (TELA) Bsecond fifth; percentile 27.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $47.1M; last close $1.06 Warnings: fortress balance sheet; 8 of 14 inputs | B | 27.3 | $47.1M | -50% | fortress balance sheet |
| 103 | Alphatec Holdings, Inc. (ATEC) Alphatec Holdings, Inc. (ATEC) Bsecond fifth; percentile 27.6 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.6B; last close $10.36 No active warnings; 9 of 14 inputs | B | 27.6 | $1.6B | -36% | |
| 104 | Agape ATP Corp. (ATPC) Agape ATP Corp. (ATPC) Bsecond fifth; percentile 27.8 Nasdaq · Services-Health Services market equity $2.1M; last close $2.10 Warnings: late filer; 8 of 14 inputs | B | 27.8 | $2.1M | -96% | late filer |
| 105 | Agios Pharmaceuticals, Inc. (AGIO) Agios Pharmaceuticals, Inc. (AGIO) Bsecond fifth; percentile 28.1 Nasdaq · Pharmaceutical Preparations market equity $1.9B; last close $31.92 Warnings: short runway; 8 of 14 inputs | B | 28.1 | $1.9B | -16% | short runway |
| 106 | Myriad Genetics Inc. (MYGN) Myriad Genetics Inc. (MYGN) Bsecond fifth; percentile 28.4 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $401.7M; last close $4.17 Warnings: fortress balance sheet; 7 of 14 inputs | B | 28.4 | $401.7M | -55% | fortress balance sheet |
| 107 | DocGo Inc. (DCGO) DocGo Inc. (DCGO) Bsecond fifth; percentile 28.6 Nasdaq · Services-Health Services market equity $33.5M; last close $0.34 Warnings: late filer, fortress balance sheet; 7 of 14 inputs | B | 28.6 | $33.5M | -72% | late filer, fortress balance sheet |
| 108 | Healthcare Services Group Inc. (HCSG) Healthcare Services Group Inc. (HCSG) Bsecond fifth; percentile 28.9 Nasdaq · Services-Nursing & Personal Care Facilities market equity $1.4B; last close $20.66 No active warnings; 7 of 14 inputs | B | 28.9 | $1.4B | +31% | |
| 109 | Staar Surgical Co. (STAA) Staar Surgical Co. (STAA) Bsecond fifth; percentile 29.2 Nasdaq · Ophthalmic Goods market equity $1.1B; last close $22.38 No active warnings; 9 of 14 inputs | B | 29.2 | $1.1B | -16% | |
| 110 | Cytokinetics Inc. (CYTK) Cytokinetics Inc. (CYTK) Bsecond fifth; percentile 29.5 Nasdaq · Pharmaceutical Preparations market equity $8.6B; last close $62.00 Warnings: short runway; 8 of 14 inputs | B | 29.5 | $8.6B | +29% | short runway |
| 111 | Steris plc (STE) Steris plc (STE) Bsecond fifth; percentile 29.7 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $20.5B; last close $210.74 No active warnings; 10 of 14 inputs | B | 29.7 | $20.5B | -6% | |
| 112 | Cadre Holdings, Inc. (CDRE) Cadre Holdings, Inc. (CDRE) Bsecond fifth; percentile 30.0 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $1.1B; last close $24.80 No active warnings; 10 of 14 inputs | B | 30.0 | $1.1B | -18% | |
| 113 | MSA Safety Inc. (MSA) MSA Safety Inc. (MSA) Bsecond fifth; percentile 30.3 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies last close $177.94 No active warnings; 11 of 14 inputs | B | 30.3 | +10% | ||
| 114 | BioNexus Gene Lab Corp. (BGLC) BioNexus Gene Lab Corp. (BGLC) Bsecond fifth; percentile 30.5 Nasdaq · Services-Medical Laboratories market equity $3.7M; last close $1.24 Warnings: dilution, late filer; 8 of 14 inputs | B | 30.5 | $3.7M | -73% | dilution, late filer |
| 115 | Arcutis Biotherapeutics, Inc. (ARQT) Arcutis Biotherapeutics, Inc. (ARQT) Bsecond fifth; percentile 30.8 Nasdaq · Pharmaceutical Preparations market equity $3.1B; last close $24.49 No active warnings; 7 of 14 inputs | B | 30.8 | $3.1B | +27% | |
| 116 | Bio-Techne Corp. (TECH) Bio-Techne Corp. (TECH) Bsecond fifth; percentile 31.1 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $11.4B; last close $72.46 Warnings: fortress balance sheet; 11 of 14 inputs | B | 31.1 | $11.4B | +31% | fortress balance sheet |
| 117 | Verastem, Inc. (VSTM) Verastem, Inc. (VSTM) Bsecond fifth; percentile 31.4 Nasdaq · Pharmaceutical Preparations market equity $734.5M; last close $8.11 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | B | 31.4 | $734.5M | -18% | dilution, fortress balance sheet |
| 118 | Stryker Corp. (SYK) Stryker Corp. (SYK) Bsecond fifth; percentile 31.6 NYSE · Surgical & Medical Instruments & Apparatus market equity $106.2B; last close $276.95 No active warnings; 10 of 14 inputs | B | 31.6 | $106.2B | -12% | |
| 119 | Usana Health Sciences Inc. (USNA) Usana Health Sciences Inc. (USNA) Bsecond fifth; percentile 31.9 NYSE · Medicinal Chemicals & Botanical Products market equity $270.9M; last close $14.65 No active warnings; 10 of 14 inputs | B | 31.9 | $270.9M | -48% | |
| 120 | Eton Pharmaceuticals, Inc. (ETON) Eton Pharmaceuticals, Inc. (ETON) Bsecond fifth; percentile 32.2 Nasdaq · Pharmaceutical Preparations market equity $1.6B; last close $54.73 No active warnings; 9 of 14 inputs | B | 32.2 | $1.6B | +178% | |
| 121 | CVRx, Inc. (CVRX) CVRx, Inc. (CVRX) Bsecond fifth; percentile 32.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $44.8M; last close $1.67 No active warnings; 8 of 14 inputs | B | 32.4 | $44.8M | -63% | |
| 122 | Koru Medical Systems, Inc. (KRMD) Koru Medical Systems, Inc. (KRMD) Bsecond fifth; percentile 32.7 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $138.5M; last close $3.01 Warnings: fortress balance sheet; 8 of 14 inputs | B | 32.7 | $138.5M | -14% | fortress balance sheet |
| 123 | CorMedix Inc. (CRMD) CorMedix Inc. (CRMD) Bsecond fifth; percentile 33.0 Nasdaq · Pharmaceutical Preparations market equity $570.6M; last close $7.31 No active warnings; 7 of 14 inputs | B | 33.0 | $570.6M | -29% | |
| 124 | InfuSystem Holdings, Inc. (INFU) InfuSystem Holdings, Inc. (INFU) Bsecond fifth; percentile 33.2 NYSE · Surgical & Medical Instruments & Apparatus market equity $267.1M; last close $13.43 No active warnings; 12 of 14 inputs | B | 33.2 | $267.1M | +17% | |
| 125 | Chemed Corp. (CHE) Chemed Corp. (CHE) Bsecond fifth; percentile 33.5 NYSE · Services-Home Health Care Services market equity $6.5B; last close $498.81 No active warnings; 11 of 14 inputs | B | 33.5 | $6.5B | +16% | |
| 126 | Apyx Medical Corp. (APYX) Apyx Medical Corp. (APYX) Bsecond fifth; percentile 33.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $99.4M; last close $2.40 No active warnings; 8 of 14 inputs | B | 33.8 | $99.4M | +43% | |
| 127 | Tandem Diabetes Care Inc. (TNDM) Tandem Diabetes Care Inc. (TNDM) Bsecond fifth; percentile 34.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.1B; last close $15.68 No active warnings; 9 of 14 inputs | B | 34.1 | $1.1B | +81% | |
| 128 | BrightSpring Health Services, Inc. (BTSG) BrightSpring Health Services, Inc. (BTSG) Bsecond fifth; percentile 34.5 Nasdaq · Services-Home Health Care Services last close $63.69 No active warnings; 8 of 14 inputs | B | 34.5 | +98% | ||
| 129 | BrightSpring Health Services, Inc. (BTSGU) BrightSpring Health Services, Inc. (BTSGU) Bsecond fifth; percentile 34.5 Nasdaq · Services-Home Health Care Services last close $185.87 No active warnings; 8 of 14 inputs | B | 34.5 | +95% | ||
| 130 | Glaukos Corp. (GKOS) Glaukos Corp. (GKOS) Bsecond fifth; percentile 34.9 NYSE · Surgical & Medical Instruments & Apparatus market equity $9.5B; last close $161.17 Warnings: fortress balance sheet; 8 of 14 inputs | B | 34.9 | $9.5B | +120% | fortress balance sheet |
| 131 | Fitlife Brands, Inc. (FTLF) Fitlife Brands, Inc. (FTLF) Bsecond fifth; percentile 35.1 Nasdaq · Medicinal Chemicals & Botanical Products market equity $81.7M; last close $8.56 No active warnings; 8 of 14 inputs | B | 35.1 | $81.7M | -49% | |
| 132 | Insmed Inc. (INSM) Insmed Inc. (INSM) Bsecond fifth; percentile 35.4 Nasdaq · Pharmaceutical Preparations market equity $21.9B; last close $100.57 No active warnings; 10 of 14 inputs | B | 35.4 | $21.9B | -15% | |
| 133 | Establishment Labs Holdings Inc. (ESTA) Establishment Labs Holdings Inc. (ESTA) Bsecond fifth; percentile 35.7 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $1.8B; last close $60.54 Warnings: fortress balance sheet; 8 of 14 inputs | B | 35.7 | $1.8B | +69% | fortress balance sheet |
| 134 | Ionis Pharmaceuticals Inc. (IONS) Ionis Pharmaceuticals Inc. (IONS) Bsecond fifth; percentile 35.9 Nasdaq · Pharmaceutical Preparations market equity $7.2B; last close $43.29 No active warnings; 10 of 14 inputs | B | 35.9 | $7.2B | -8% | |
| 135 | Biocryst Pharmaceuticals Inc. (BCRX) Biocryst Pharmaceuticals Inc. (BCRX) Bsecond fifth; percentile 36.2 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.1B; last close $8.29 Warnings: fortress balance sheet; 10 of 14 inputs | B | 36.2 | $2.1B | +28% | fortress balance sheet |
| 136 | Tenet Healthcare Corp. (THC) Tenet Healthcare Corp. (THC) Bsecond fifth; percentile 36.5 NYSE · Services-General Medical & Surgical Hospitals, NEC market equity $21.0B; last close $260.68 No active warnings; 10 of 14 inputs | B | 36.5 | $21.0B | +31% | |
| 137 | Sanuwave Health, Inc. (SNWV) Sanuwave Health, Inc. (SNWV) Bsecond fifth; percentile 36.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $50.3M; last close $5.78 No active warnings; 10 of 14 inputs | B | 36.8 | $50.3M | -87% | |
| 138 | LifeMD, Inc. (LFMD) LifeMD, Inc. (LFMD) Bsecond fifth; percentile 37.2 Nasdaq · Services-Offices & Clinics of Doctors of Medicine last close $2.65 Warnings: late filer; 8 of 14 inputs | B | 37.2 | -54% | late filer | |
| 139 | LifeMD, Inc. (LFMDP) LifeMD, Inc. (LFMDP) Bsecond fifth; percentile 37.2 Nasdaq · Services-Offices & Clinics of Doctors of Medicine last close $23.53 Warnings: late filer; 8 of 14 inputs | B | 37.2 | +7% | late filer | |
| 140 | Collegium Pharmaceutical, Inc. (COLL) Collegium Pharmaceutical, Inc. (COLL) B/Con the B/C boundary; percentile 37.6 Nasdaq · Pharmaceutical Preparations market equity $719.8M; last close $22.11 Warnings: fortress balance sheet; 11 of 14 inputs | B/C | 37.6 | $719.8M | -30% | fortress balance sheet |
| 141 | Sunshine Biopharma Inc. (SBFM) Sunshine Biopharma Inc. (SBFM) B/Con the B/C boundary; percentile 38.0 Nasdaq · Pharmaceutical Preparations last close $0.43 Warnings: late filer; 7 of 14 inputs | B/C | 38.0 | -92% | late filer | |
| 142 | Sunshine Biopharma Inc. (SBFMW) Sunshine Biopharma Inc. (SBFMW) B/Con the B/C boundary; percentile 38.0 Nasdaq · Pharmaceutical Preparations last close $0.03 Warnings: late filer; 7 of 14 inputs | B/C | 38.0 | -79% | late filer | |
| 143 | Artivion, Inc. (AORT) Artivion, Inc. (AORT) B/Con the B/C boundary; percentile 38.4 NYSE · Surgical & Medical Instruments & Apparatus market equity $1.0B; last close $21.18 No active warnings; 11 of 14 inputs | B/C | 38.4 | $1.0B | -36% | |
| 144 | Lakeland Industries Inc. (LAKE) Lakeland Industries Inc. (LAKE) B/Con the B/C boundary; percentile 38.6 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $100.2M; last close $10.10 Warnings: late filer, fortress balance sheet; 8 of 14 inputs | B/C | 38.6 | $100.2M | -21% | late filer, fortress balance sheet |
| 145 | LifeStance Health Group, Inc. (LFST) LifeStance Health Group, Inc. (LFST) B/Con the B/C boundary; percentile 38.9 Nasdaq · Services-Health Services market equity $4.6B; last close $12.05 No active warnings; 10 of 14 inputs | B/C | 38.9 | $4.6B | +125% | |
| 146 | UroGen Pharma Ltd. (URGN) UroGen Pharma Ltd. (URGN) B/Con the B/C boundary; percentile 39.2 Nasdaq · Pharmaceutical Preparations market equity $1.8B; last close $36.96 Warnings: short runway; 9 of 14 inputs | B/C | 39.2 | $1.8B | +116% | short runway |
| 147 | Biolife Solutions Inc. (BLFS) Biolife Solutions Inc. (BLFS) B/Con the B/C boundary; percentile 39.5 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $1.9B; last close $38.60 Warnings: fortress balance sheet; 7 of 14 inputs | B/C | 39.5 | $1.9B | +45% | fortress balance sheet |
| 148 | Celldex Therapeutics, Inc. (CLDX) Celldex Therapeutics, Inc. (CLDX) B/Con the B/C boundary; percentile 39.7 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $2.3B; last close $29.29 Warnings: short runway; 9 of 14 inputs | B/C | 39.7 | $2.3B | +53% | short runway |
| 149 | National Healthcare Corp. (NHC) National Healthcare Corp. (NHC) B/Con the B/C boundary; percentile 40.0 NYSE · Services-Skilled Nursing Care Facilities market equity $3.5B; last close $223.10 Warnings: fortress balance sheet; 9 of 14 inputs | B/C | 40.0 | $3.5B | +80% | fortress balance sheet |
| 150 | ImmunityBio, Inc. (IBRX) ImmunityBio, Inc. (IBRX) B/Con the B/C boundary; percentile 40.3 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $10.5B; last close $9.91 Warnings: short runway; 9 of 14 inputs | B/C | 40.3 | $10.5B | +223% | short runway |
| 151 | Shattuck Labs, Inc. (STTK) Shattuck Labs, Inc. (STTK) B/Con the B/C boundary; percentile 40.5 Nasdaq · Pharmaceutical Preparations market equity $568.1M; last close $5.66 Warnings: dilution; 7 of 14 inputs | B/C | 40.5 | $568.1M | +193% | dilution |
| 152 | Myomo, Inc. (MYO) Myomo, Inc. (MYO) B/Con the B/C boundary; percentile 40.8 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $55.8M; last close $1.40 Warnings: fortress balance sheet; 9 of 14 inputs | B/C | 40.8 | $55.8M | +67% | fortress balance sheet |
| 153 | Lifevantage Corp. (LFVN) Lifevantage Corp. (LFVN) B/Con the B/C boundary; percentile 41.1 Nasdaq · Pharmaceutical Preparations market equity $75.0M; last close $5.99 No active warnings; 10 of 14 inputs | B/C | 41.1 | $75.0M | -34% | |
| 154 | Repligen Corp. (RGEN) Repligen Corp. (RGEN) B/Con the B/C boundary; percentile 41.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $9.2B; last close $163.99 Warnings: late filer, fortress balance sheet; 12 of 14 inputs | B/C | 41.4 | $9.2B | +35% | late filer, fortress balance sheet |
| 155 | Envista Holdings Corp. (NVST) Envista Holdings Corp. (NVST) B/Con the B/C boundary; percentile 41.6 NYSE · Dental Equipment & Supplies market equity $3.6B; last close $22.71 No active warnings; 11 of 14 inputs | B/C | 41.6 | $3.6B | +33% | |
| 156 | Xeris Biopharma Holdings, Inc. (XERS) Xeris Biopharma Holdings, Inc. (XERS) B/Con the B/C boundary; percentile 41.9 Nasdaq · Pharmaceutical Preparations market equity $1.9B; last close $10.19 No active warnings; 8 of 14 inputs | B/C | 41.9 | $1.9B | +4% | |
| 157 | Sight Sciences, Inc. (SGHT) Sight Sciences, Inc. (SGHT) B/Con the B/C boundary; percentile 42.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $466.6M; last close $8.48 Warnings: fortress balance sheet; 9 of 14 inputs | B/C | 42.2 | $466.6M | +147% | fortress balance sheet |
| 158 | Community Health Systems Inc. (CYH) Community Health Systems Inc. (CYH) B/Con the B/C boundary; percentile 42.4 NYSE · Services-General Medical & Surgical Hospitals, NEC market equity $385.0M; last close $2.72 No active warnings; 9 of 14 inputs | B/C | 42.4 | $385.0M | -9% | |
| 159 | Ligand Pharmaceuticals Inc. (LGND) Ligand Pharmaceuticals Inc. (LGND) Cmiddle fifth; percentile 42.7 Nasdaq · Pharmaceutical Preparations last close $295.45 No active warnings; 7 of 14 inputs | C | 42.7 | +60% | ||
| 160 | Nephros Inc. (NEPH) Nephros Inc. (NEPH) Cmiddle fifth; percentile 43.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $35.7M; last close $3.28 Warnings: fortress balance sheet; 8 of 14 inputs | C | 43.0 | $35.7M | -10% | fortress balance sheet |
| 161 | Immucell Corp. (ICCC) Immucell Corp. (ICCC) Cmiddle fifth; percentile 43.2 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $88.6M; last close $9.89 No active warnings; 9 of 14 inputs | C | 43.2 | $88.6M | +57% | |
| 162 | Innoviva, Inc. (INVA) Innoviva, Inc. (INVA) Cmiddle fifth; percentile 43.5 Nasdaq · Pharmaceutical Preparations market equity $1.5B; last close $20.86 No active warnings; 8 of 14 inputs | C | 43.5 | $1.5B | +14% | |
| 163 | Addus HomeCare Corp. (ADUS) Addus HomeCare Corp. (ADUS) Cmiddle fifth; percentile 43.8 Nasdaq · Services-Home Health Care Services market equity $2.1B; last close $114.59 No active warnings; 9 of 14 inputs | C | 43.8 | $2.1B | -3% | |
| 164 | NovoCure Ltd. (NVCR) NovoCure Ltd. (NVCR) Cmiddle fifth; percentile 44.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.7B; last close $14.19 Warnings: fortress balance sheet; 9 of 14 inputs | C | 44.1 | $1.7B | +37% | fortress balance sheet |
| 165 | Medtronic plc (MDT) Medtronic plc (MDT) Cmiddle fifth; percentile 44.3 NYSE · Electromedical & Electrotherapeutic Apparatus market equity $112.2B; last close $87.71 No active warnings; 13 of 14 inputs | C | 44.3 | $112.2B | -3% | |
| 166 | Avita Medical, Inc. (RCEL) Avita Medical, Inc. (RCEL) Cmiddle fifth; percentile 44.6 Nasdaq · Surgical & Medical Instruments & Apparatus last close $13.35 Warnings: short runway; 7 of 14 inputs | C | 44.6 | +98% | short runway | |
| 167 | Johnson & Johnson (JNJ) Johnson & Johnson (JNJ) Cmiddle fifth; percentile 44.9 NYSE · Pharmaceutical Preparations market equity $618.1B; last close $256.48 No active warnings; 9 of 14 inputs | C | 44.9 | $618.1B | +46% | |
| 168 | Lensar, Inc. (LNSR) Lensar, Inc. (LNSR) Cmiddle fifth; percentile 45.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $79.2M; last close $6.46 No active warnings; 8 of 14 inputs | C | 45.1 | $79.2M | -32% | |
| 169 | Integer Holdings Corp. (ITGR) Integer Holdings Corp. (ITGR) Cmiddle fifth; percentile 45.4 NYSE · Electromedical & Electrotherapeutic Apparatus market equity $4.3B; last close $126.65 No active warnings; 12 of 14 inputs | C | 45.4 | $4.3B | +21% | |
| 170 | Zimmer Biomet Holdings, Inc. (ZBH) Zimmer Biomet Holdings, Inc. (ZBH) Cmiddle fifth; percentile 45.7 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $17.0B; last close $88.86 No active warnings; 10 of 14 inputs | C | 45.7 | $17.0B | +2% | |
| 171 | Orasure Technologies Inc. (OSUR) Orasure Technologies Inc. (OSUR) Cmiddle fifth; percentile 45.9 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $261.7M; last close $3.79 No active warnings; 8 of 14 inputs | C | 45.9 | $261.7M | +12% | |
| 172 | Pediatrix Medical Group, Inc. (MD) Pediatrix Medical Group, Inc. (MD) Cmiddle fifth; percentile 46.2 NYSE · Services-Hospitals market equity $2.1B; last close $26.27 No active warnings; 8 of 14 inputs | C | 46.2 | $2.1B | +57% | |
| 173 | Enovis Corp. (ENOV) Enovis Corp. (ENOV) Cmiddle fifth; percentile 46.5 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $1.0B; last close $17.44 No active warnings; 10 of 14 inputs | C | 46.5 | $1.0B | -19% | |
| 174 | Align Technology Inc. (ALGN) Align Technology Inc. (ALGN) Cmiddle fifth; percentile 46.8 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $10.0B; last close $140.95 No active warnings; 10 of 14 inputs | C | 46.8 | $10.0B | +28% | |
| 175 | ClearPoint Neuro, Inc. (CLPT) ClearPoint Neuro, Inc. (CLPT) Cmiddle fifth; percentile 47.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $320.0M; last close $10.47 No active warnings; 8 of 14 inputs | C | 47.0 | $320.0M | -31% | |
| 176 | Anika Therapeutics, Inc. (ANIK) Anika Therapeutics, Inc. (ANIK) Cmiddle fifth; percentile 47.3 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $257.4M; last close $19.20 Warnings: fortress balance sheet; 7 of 14 inputs | C | 47.3 | $257.4M | +122% | fortress balance sheet |
| 177 | Davita Inc. (DVA) Davita Inc. (DVA) Cmiddle fifth; percentile 47.6 NYSE · Services-Misc Health & Allied Services, NEC market equity $11.3B; last close $177.21 No active warnings; 12 of 14 inputs | C | 47.6 | $11.3B | +32% | |
| 178 | Kymera Therapeutics, Inc. (KYMR) Kymera Therapeutics, Inc. (KYMR) Cmiddle fifth; percentile 47.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $9.1B; last close $109.34 Warnings: dilution; 7 of 14 inputs | C | 47.8 | $9.1B | +110% | dilution |
| 179 | Scynexis Inc. (SCYX) Scynexis Inc. (SCYX) Cmiddle fifth; percentile 48.1 Nasdaq · Pharmaceutical Preparations market equity $42.0M; last close $4.19 Warnings: fortress balance sheet; 7 of 14 inputs | C | 48.1 | $42.0M | -15% | fortress balance sheet |
| 180 | Amneal Pharmaceuticals, Inc. (AMRX) Amneal Pharmaceuticals, Inc. (AMRX) Cmiddle fifth; percentile 48.4 Nasdaq · Pharmaceutical Preparations market equity $6.3B; last close $19.65 No active warnings; 11 of 14 inputs | C | 48.4 | $6.3B | +75% | |
| 181 | Macrogenics Inc. (MGNX) Macrogenics Inc. (MGNX) Cmiddle fifth; percentile 48.6 Nasdaq · Pharmaceutical Preparations market equity $226.1M; last close $3.54 No active warnings; 8 of 14 inputs | C | 48.6 | $226.1M | +137% | |
| 182 | Savara Inc. (SVRA) Savara Inc. (SVRA) Cmiddle fifth; percentile 48.9 Nasdaq · Pharmaceutical Preparations market equity $992.4M; last close $4.84 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | C | 48.9 | $992.4M | +51% | short runway, fortress balance sheet |
| 183 | Biodesix Inc. (BDSX) Biodesix Inc. (BDSX) Cmiddle fifth; percentile 49.2 Nasdaq · Services-Medical Laboratories market equity $270.4M; last close $25.36 Warnings: dilution; 7 of 14 inputs | C | 49.2 | $270.4M | +249% | dilution |
| 184 | Evolus, Inc. (EOLS) Evolus, Inc. (EOLS) Cmiddle fifth; percentile 49.5 Nasdaq · Pharmaceutical Preparations market equity $515.2M; last close $7.80 No active warnings; 8 of 14 inputs | C | 49.5 | $515.2M | +48% | |
| 185 | Neogen Corp. (NEOG) Neogen Corp. (NEOG) Cmiddle fifth; percentile 49.7 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $2.6B; last close $11.71 Warnings: late filer; 9 of 14 inputs | C | 49.7 | $2.6B | +102% | late filer |
| 186 | Nurix Therapeutics, Inc. (NRIX) Nurix Therapeutics, Inc. (NRIX) Cmiddle fifth; percentile 50.0 Nasdaq · Pharmaceutical Preparations market equity $2.3B; last close $22.20 Warnings: dilution, short runway; 7 of 14 inputs | C | 50.0 | $2.3B | +179% | dilution, short runway |
| 187 | Pacira BioSciences, Inc. (PCRX) Pacira BioSciences, Inc. (PCRX) Cmiddle fifth; percentile 50.3 Nasdaq · Pharmaceutical Preparations market equity $1.5B; last close $36.41 No active warnings; 11 of 14 inputs | C | 50.3 | $1.5B | +1% | |
| 188 | Neuroone Medical Technologies Corp. (NMTC) Neuroone Medical Technologies Corp. (NMTC) Cmiddle fifth; percentile 50.5 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $9.8M; last close $1.11 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | C | 50.5 | $9.8M | -68% | short runway, fortress balance sheet |
| 189 | RadNet, Inc. (RDNT) RadNet, Inc. (RDNT) Cmiddle fifth; percentile 50.8 Nasdaq · Services-Medical Laboratories market equity $5.4B; last close $68.25 No active warnings; 8 of 14 inputs | C | 50.8 | $5.4B | -1% | |
| 190 | Schrodinger, Inc. (SDGR) Schrodinger, Inc. (SDGR) Cmiddle fifth; percentile 51.1 Nasdaq · Pharmaceutical Preparations market equity $1.7B; last close $26.40 No active warnings; 8 of 14 inputs | C | 51.1 | $1.7B | -3% | |
| 191 | Zai Lab Ltd. (ZLAB) Zai Lab Ltd. (ZLAB) Cmiddle fifth; percentile 51.4 Nasdaq · Pharmaceutical Preparations market equity $27.8B; last close $24.84 No active warnings; 8 of 14 inputs | C | 51.4 | $27.8B | -25% | |
| 192 | Recursion Pharmaceuticals, Inc. (RXRX) Recursion Pharmaceuticals, Inc. (RXRX) Cmiddle fifth; percentile 51.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.1B; last close $3.94 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | C | 51.6 | $2.1B | -30% | dilution, fortress balance sheet |
| 193 | Haemonetics Corp. (HAE) Haemonetics Corp. (HAE) Cmiddle fifth; percentile 51.9 NYSE · Surgical & Medical Instruments & Apparatus market equity $5.4B; last close $119.53 No active warnings; 11 of 14 inputs | C | 51.9 | $5.4B | +111% | |
| 194 | Solventum Corp. (SOLV) Solventum Corp. (SOLV) Cmiddle fifth; percentile 52.2 NYSE · Surgical & Medical Instruments & Apparatus market equity $14.7B; last close $86.37 No active warnings; 8 of 14 inputs | C | 52.2 | $14.7B | +25% | |
| 195 | Aveanna Healthcare Holdings, Inc. (AVAH) Aveanna Healthcare Holdings, Inc. (AVAH) Cmiddle fifth; percentile 52.4 Nasdaq · Services-Home Health Care Services market equity $2.7B; last close $12.24 No active warnings; 10 of 14 inputs | C | 52.4 | $2.7B | +51% | |
| 196 | Nexgel, Inc. (NXGL) Nexgel, Inc. (NXGL) Cmiddle fifth; percentile 52.8 Nasdaq · Surgical & Medical Instruments & Apparatus last close $0.15 Warnings: late filer; 7 of 14 inputs | C | 52.8 | -85% | late filer | |
| 197 | Nexgel, Inc. (NXGLW) Nexgel, Inc. (NXGLW) Cmiddle fifth; percentile 52.8 Nasdaq · Surgical & Medical Instruments & Apparatus last close $0.01 Warnings: late filer; 7 of 14 inputs | C | 52.8 | -94% | late filer | |
| 198 | Perrigo Co. plc (PRGO) Perrigo Co. plc (PRGO) Cmiddle fifth; percentile 53.2 NYSE · Pharmaceutical Preparations market equity $2.0B; last close $14.50 No active warnings; 9 of 14 inputs | C | 53.2 | $2.0B | -31% | |
| 199 | Sotera Health Co. (SHC) Sotera Health Co. (SHC) Cmiddle fifth; percentile 53.5 Nasdaq · Services-Misc Health & Allied Services, NEC market equity $5.1B; last close $17.84 No active warnings; 8 of 14 inputs | C | 53.5 | $5.1B | +20% | |
| 200 | Universal Health Services Inc. (UHS) Universal Health Services Inc. (UHS) Cmiddle fifth; percentile 53.8 NYSE · Services-General Medical & Surgical Hospitals, NEC last close $175.66 No active warnings; 9 of 14 inputs | C | 53.8 | -17% | ||
| 201 | Roivant Sciences Ltd. (ROIV) Roivant Sciences Ltd. (ROIV) Cmiddle fifth; percentile 54.1 Nasdaq · Pharmaceutical Preparations market equity $24.7B; last close $34.22 Warnings: fortress balance sheet; 7 of 14 inputs | C | 54.1 | $24.7B | +129% | fortress balance sheet |
| 202 | Emergent BioSolutions Inc. (EBS) Emergent BioSolutions Inc. (EBS) Cmiddle fifth; percentile 54.3 NYSE · Pharmaceutical Preparations market equity $349.2M; last close $6.82 No active warnings; 10 of 14 inputs | C | 54.3 | $349.2M | -31% | |
| 203 | Abbott Laboratories (ABT) Abbott Laboratories (ABT) Cmiddle fifth; percentile 54.6 NYSE · Pharmaceutical Preparations market equity $171.6B; last close $98.49 No active warnings; 11 of 14 inputs | C | 54.6 | $171.6B | -16% | |
| 204 | Teladoc Health, Inc. (TDOC) Teladoc Health, Inc. (TDOC) Cmiddle fifth; percentile 54.9 NYSE · Services-Offices & Clinics of Doctors of Medicine market equity $1.0B; last close $5.53 Warnings: fortress balance sheet; 7 of 14 inputs | C | 54.9 | $1.0B | -18% | fortress balance sheet |
| 205 | Neuronetics, Inc. (STIM) Neuronetics, Inc. (STIM) Cmiddle fifth; percentile 55.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $163.1M; last close $2.15 No active warnings; 8 of 14 inputs | C | 55.1 | $163.1M | +4% | |
| 206 | Regenxbio Inc. (RGNX) Regenxbio Inc. (RGNX) Cmiddle fifth; percentile 55.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $534.0M; last close $8.08 Warnings: short runway; 7 of 14 inputs | C | 55.4 | $534.0M | -2% | short runway |
| 207 | ELI Lilly & Co. (LLY) ELI Lilly & Co. (LLY) Cmiddle fifth; percentile 55.7 NYSE · Pharmaceutical Preparations market equity $1.1T; last close $1,169.61 No active warnings; 7 of 14 inputs | C | 55.7 | $1.1T | +53% | |
| 208 | Cabaletta Bio, Inc. (CABA) Cabaletta Bio, Inc. (CABA) Cmiddle fifth; percentile 55.9 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $330.6M; last close $1.95 Warnings: dilution; 7 of 14 inputs | C | 55.9 | $330.6M | +33% | dilution |
| 209 | AdaptHealth Corp. (AHCO) AdaptHealth Corp. (AHCO) Cmiddle fifth; percentile 56.2 Nasdaq · Services-Home Health Care Services market equity $826.9M; last close $6.07 No active warnings; 8 of 14 inputs | C | 56.2 | $826.9M | -38% | |
| 210 | Inogen Inc. (INGN) Inogen Inc. (INGN) Cmiddle fifth; percentile 56.5 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $157.6M; last close $5.94 Warnings: fortress balance sheet; 8 of 14 inputs | C | 56.5 | $157.6M | -34% | fortress balance sheet |
| 211 | Cooper Companies, Inc. (COO) Cooper Companies, Inc. (COO) Cmiddle fifth; percentile 56.8 Nasdaq · Ophthalmic Goods market equity $10.3B; last close $54.29 No active warnings; 12 of 14 inputs | C | 56.8 | $10.3B | +2% | |
| 212 | Aquestive Therapeutics, Inc. (AQST) Aquestive Therapeutics, Inc. (AQST) Cmiddle fifth; percentile 57.0 Nasdaq · Pharmaceutical Preparations market equity $597.4M; last close $4.77 No active warnings; 7 of 14 inputs | C | 57.0 | $597.4M | -9% | |
| 213 | Tango Therapeutics, Inc. (TNGX) Tango Therapeutics, Inc. (TNGX) Cmiddle fifth; percentile 57.3 Nasdaq · Pharmaceutical Preparations market equity $3.8B; last close $22.56 Warnings: dilution; 7 of 14 inputs | C | 57.3 | $3.8B | +172% | dilution |
| 214 | Cryo Cell International Inc. (CCEL) Cryo Cell International Inc. (CCEL) C/Don the C/D boundary; percentile 57.6 NYSE · Services-Misc Health & Allied Services, NEC market equity $33.6M; last close $3.76 No active warnings; 11 of 14 inputs | C/D | 57.6 | $33.6M | -9% | |
| 215 | electroCore, Inc. (ECOR) electroCore, Inc. (ECOR) C/Don the C/D boundary; percentile 57.8 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $85.7M; last close $9.47 No active warnings; 9 of 14 inputs | C/D | 57.8 | $85.7M | +92% | |
| 216 | Rocket Pharmaceuticals, Inc. (RCKT) Rocket Pharmaceuticals, Inc. (RCKT) C/Don the C/D boundary; percentile 58.1 Nasdaq · Pharmaceutical Preparations market equity $288.7M; last close $2.62 Warnings: degenerate inputs; 7 of 14 inputs | C/D | 58.1 | $288.7M | +14% | degenerate inputs |
| 217 | Prestige Consumer Healthcare Inc. (PBH) Prestige Consumer Healthcare Inc. (PBH) C/Don the C/D boundary; percentile 58.4 NYSE · Pharmaceutical Preparations market equity $2.3B; last close $47.85 No active warnings; 12 of 14 inputs | C/D | 58.4 | $2.3B | -17% | |
| 218 | Becton Dickinson & Co. (BDX) Becton Dickinson & Co. (BDX) C/Don the C/D boundary; percentile 58.6 NYSE · Surgical & Medical Instruments & Apparatus market equity $49.8B; last close $182.65 No active warnings; 10 of 14 inputs | C/D | 58.6 | $49.8B | +30% | |
| 219 | Option Care Health, Inc. (OPCH) Option Care Health, Inc. (OPCH) C/Don the C/D boundary; percentile 58.9 Nasdaq · Services-Home Health Care Services market equity $4.9B; last close $31.06 No active warnings; 12 of 14 inputs | C/D | 58.9 | $4.9B | -16% | |
| 220 | Cryoport, Inc. (CYRX) Cryoport, Inc. (CYRX) C/Don the C/D boundary; percentile 59.2 Nasdaq · Pharmaceutical Preparations market equity $856.0M; last close $16.91 Warnings: late filer; 9 of 14 inputs | C/D | 59.2 | $856.0M | +69% | late filer |
| 221 | GeneDx Holdings Corp. (WGS) GeneDx Holdings Corp. (WGS) C/Don the C/D boundary; percentile 59.5 Nasdaq · Services-Health Services market equity $2.0B; last close $67.69 Warnings: fortress balance sheet; 10 of 14 inputs | C/D | 59.5 | $2.0B | -21% | fortress balance sheet |
| 222 | Trulieve Cannabis Corp. (TRLV) Trulieve Cannabis Corp. (TRLV) C/Don the C/D boundary; percentile 59.7 NYSE · Medicinal Chemicals & Botanical Products market equity $2.0B; last close $10.40 Warnings: fortress balance sheet; 7 of 14 inputs | C/D | 59.7 | $2.0B | n/a | fortress balance sheet |
| 223 | Labcorp Holdings Inc. (LH) Labcorp Holdings Inc. (LH) C/Don the C/D boundary; percentile 60.0 NYSE · Services-Medical Laboratories market equity $25.5B; last close $314.20 No active warnings; 10 of 14 inputs | C/D | 60.0 | $25.5B | +17% | |
| 224 | Perspective Therapeutics, Inc. (CATX) Perspective Therapeutics, Inc. (CATX) C/Don the C/D boundary; percentile 60.3 NYSE · Pharmaceutical Preparations market equity $309.4M; last close $2.71 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | C/D | 60.3 | $309.4M | -8% | dilution, fortress balance sheet |
| 225 | ARS Pharmaceuticals, Inc. (SPRY) ARS Pharmaceuticals, Inc. (SPRY) C/Don the C/D boundary; percentile 60.5 Nasdaq · Pharmaceutical Preparations market equity $453.5M; last close $4.57 Warnings: short runway; 7 of 14 inputs | C/D | 60.5 | $453.5M | -40% | short runway |
| 226 | Twist Bioscience Corp. (TWST) Twist Bioscience Corp. (TWST) C/Don the C/D boundary; percentile 60.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $9.5B; last close $152.02 Warnings: fortress balance sheet; 9 of 14 inputs | C/D | 60.8 | $9.5B | +394% | fortress balance sheet |
| 227 | Teva Pharmaceutical Industries Ltd. (TEVA) Teva Pharmaceutical Industries Ltd. (TEVA) C/Don the C/D boundary; percentile 61.1 NYSE · Pharmaceutical Preparations market equity $45.7B; last close $39.22 No active warnings; 9 of 14 inputs | C/D | 61.1 | $45.7B | +85% | |
| 228 | Beam Therapeutics Inc. (BEAM) Beam Therapeutics Inc. (BEAM) C/Don the C/D boundary; percentile 61.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.5B; last close $24.59 No active warnings; 7 of 14 inputs | C/D | 61.4 | $2.5B | +21% | |
| 229 | Akebia Therapeutics, Inc. (AKBA) Akebia Therapeutics, Inc. (AKBA) C/Don the C/D boundary; percentile 61.6 Nasdaq · Pharmaceutical Preparations market equity $225.8M; last close $0.82 Warnings: fortress balance sheet; 9 of 14 inputs | C/D | 61.6 | $225.8M | -66% | fortress balance sheet |
| 230 | Mannkind Corp. (MNKD) Mannkind Corp. (MNKD) C/Don the C/D boundary; percentile 61.9 Nasdaq · Pharmaceutical Preparations market equity $1.1B; last close $3.42 No active warnings; 10 of 14 inputs | C/D | 61.9 | $1.1B | -25% | |
| 231 | Strata Critical Medical, Inc. (SRTA) Strata Critical Medical, Inc. (SRTA) C/Don the C/D boundary; percentile 62.2 Nasdaq · Services-Health Services market equity $395.4M; last close $4.46 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | C/D | 62.2 | $395.4M | +12% | short runway, fortress balance sheet |
| 232 | Embecta Corp. (EMBC) Embecta Corp. (EMBC) C/Don the C/D boundary; percentile 62.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $325.8M; last close $5.76 Warnings: late filer; 10 of 14 inputs | C/D | 62.4 | $325.8M | -62% | late filer |
| 233 | Biogen Inc. (BIIB) Biogen Inc. (BIIB) Dfourth fifth; percentile 62.7 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $32.2B; last close $218.35 No active warnings; 8 of 14 inputs | D | 62.7 | $32.2B | +55% | |
| 234 | Lenz Therapeutics, Inc. (LENZ) Lenz Therapeutics, Inc. (LENZ) Dfourth fifth; percentile 63.0 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $110.9M; last close $3.52 Warnings: short runway; 7 of 14 inputs | D | 63.0 | $110.9M | -89% | short runway |
| 235 | AbbVie Inc. (ABBV) AbbVie Inc. (ABBV) Dfourth fifth; percentile 63.2 NYSE · Pharmaceutical Preparations market equity $481.4B; last close $272.45 No active warnings; 12 of 14 inputs | D | 63.2 | $481.4B | +14% | |
| 236 | Caribou Biosciences, Inc. (CRBU) Caribou Biosciences, Inc. (CRBU) Dfourth fifth; percentile 63.5 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $51.6M; last close $0.48 Warnings: short runway; 7 of 14 inputs | D | 63.5 | $51.6M | -34% | short runway |
| 237 | Royalty Pharma plc (RPRX) Royalty Pharma plc (RPRX) Dfourth fifth; percentile 63.8 Nasdaq · Pharmaceutical Preparations market equity $21.8B; last close $56.22 No active warnings; 7 of 14 inputs | D | 63.8 | $21.8B | +77% | |
| 238 | Integra Lifesciences Holdings Corp. (IART) Integra Lifesciences Holdings Corp. (IART) Dfourth fifth; percentile 64.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $1.0B; last close $13.43 No active warnings; 10 of 14 inputs | D | 64.1 | $1.0B | +18% | |
| 239 | Alpha Teknova, Inc. (TKNO) Alpha Teknova, Inc. (TKNO) Dfourth fifth; percentile 64.3 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $453.1M; last close $8.45 No active warnings; 9 of 14 inputs | D | 64.3 | $453.1M | +16% | |
| 240 | Arvinas, Inc. (ARVN) Arvinas, Inc. (ARVN) Dfourth fifth; percentile 64.6 Nasdaq · Pharmaceutical Preparations market equity $491.1M; last close $7.51 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | D | 64.6 | $491.1M | +8% | short runway, fortress balance sheet |
| 241 | Organogenesis Holdings Inc. (ORGO) Organogenesis Holdings Inc. (ORGO) Dfourth fifth; percentile 64.9 Nasdaq · Pharmaceutical Preparations market equity $164.7M; last close $1.27 Warnings: fortress balance sheet; 7 of 14 inputs | D | 64.9 | $164.7M | -59% | fortress balance sheet |
| 242 | Fulgent Genetics, Inc. (FLGT) Fulgent Genetics, Inc. (FLGT) Dfourth fifth; percentile 65.1 Nasdaq · Services-Medical Laboratories market equity $572.9M; last close $20.87 Warnings: short runway; 8 of 14 inputs | D | 65.1 | $572.9M | -14% | short runway |
| 243 | Entera Bio Ltd. (ENTX) Entera Bio Ltd. (ENTX) Dfourth fifth; percentile 65.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $432.9M; last close $2.51 Warnings: degenerate inputs; 7 of 14 inputs | D | 65.4 | $432.9M | +54% | degenerate inputs |
| 244 | Dentsply Sirona Inc. (XRAY) Dentsply Sirona Inc. (XRAY) Dfourth fifth; percentile 65.7 Nasdaq · Dental Equipment & Supplies market equity $1.7B; last close $8.68 No active warnings; 9 of 14 inputs | D | 65.7 | $1.7B | -11% | |
| 245 | InspireMD, Inc. (NSPR) InspireMD, Inc. (NSPR) Dfourth fifth; percentile 65.9 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $22.3M; last close $0.47 Warnings: dilution, short runway, distress; 9 of 14 inputs | D | 65.9 | $22.3M | -63% | dilution, short runway, distress |
| 246 | Angiodynamics Inc. (ANGO) Angiodynamics Inc. (ANGO) Dfourth fifth; percentile 66.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $472.3M; last close $11.22 Warnings: fortress balance sheet; 7 of 14 inputs | D | 66.2 | $472.3M | +44% | fortress balance sheet |
| 247 | AIM ImmunoTech Inc. (AIM) AIM ImmunoTech Inc. (AIM) Dfourth fifth; percentile 66.5 NYSE · Biological Products, (No Diagnostic Substances) market equity $5.5M; last close $0.18 Warnings: late filer, degenerate inputs, distress; 8 of 14 inputs | D | 66.5 | $5.5M | -67% | late filer, degenerate inputs, distress |
| 248 | Exagen Inc. (XGN) Exagen Inc. (XGN) Dfourth fifth; percentile 66.8 Nasdaq · Services-Medical Laboratories market equity $197.9M; last close $8.15 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | D | 66.8 | $197.9M | -33% | dilution, fortress balance sheet |
| 249 | PTC Therapeutics, Inc. (PTCT) PTC Therapeutics, Inc. (PTCT) Dfourth fifth; percentile 67.0 Nasdaq · Pharmaceutical Preparations market equity $5.2B; last close $62.55 No active warnings; 8 of 14 inputs | D | 67.0 | $5.2B | +13% | |
| 250 | Cardiff Oncology, Inc. (CRDF) Cardiff Oncology, Inc. (CRDF) Dfourth fifth; percentile 67.3 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $82.5M; last close $1.07 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | D | 67.3 | $82.5M | -52% | short runway, fortress balance sheet |
| 251 | Amylyx Pharmaceuticals, Inc. (AMLX) Amylyx Pharmaceuticals, Inc. (AMLX) Dfourth fifth; percentile 67.6 Nasdaq · Pharmaceutical Preparations market equity $3.0B; last close $27.22 Warnings: short runway, degenerate inputs; 7 of 14 inputs | D | 67.6 | $3.0B | +148% | short runway, degenerate inputs |
| 252 | U S Physical Therapy Inc. (USPH) U S Physical Therapy Inc. (USPH) Dfourth fifth; percentile 67.8 NYSE · Services-Health Services market equity $1.2B; last close $83.40 No active warnings; 10 of 14 inputs | D | 67.8 | $1.2B | -6% | |
| 253 | American Shared Hospital Services (AMS) American Shared Hospital Services (AMS) Dfourth fifth; percentile 68.1 NYSE · Services-Medical Laboratories market equity $8.8M; last close $1.48 Warnings: late filer; 10 of 14 inputs | D | 68.1 | $8.8M | -49% | late filer |
| 254 | Orchestra BioMed Holdings, Inc. (OBIO) Orchestra BioMed Holdings, Inc. (OBIO) Dfourth fifth; percentile 68.4 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $344.4M; last close $5.72 Warnings: dilution, short runway, fortress balance sheet; 7 of 14 inputs | D | 68.4 | $344.4M | +103% | dilution, short runway, fortress balance sheet |
| 255 | Adaptive Biotechnologies Corp. (ADPT) Adaptive Biotechnologies Corp. (ADPT) Dfourth fifth; percentile 68.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $4.2B; last close $26.09 No active warnings; 9 of 14 inputs | D | 68.6 | $4.2B | +67% | |
| 256 | Iridex Corp. (IRIX) Iridex Corp. (IRIX) Dfourth fifth; percentile 68.9 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $15.8M; last close $0.90 Warnings: fortress balance sheet; 8 of 14 inputs | D | 68.9 | $15.8M | -37% | fortress balance sheet |
| 257 | Lyell Immunopharma, Inc. (LYEL) Lyell Immunopharma, Inc. (LYEL) Dfourth fifth; percentile 69.2 Nasdaq · Pharmaceutical Preparations market equity $215.4M; last close $8.76 Warnings: dilution, degenerate inputs; 7 of 14 inputs | D | 69.2 | $215.4M | -12% | dilution, degenerate inputs |
| 258 | Iovance Biotherapeutics, Inc. (IOVA) Iovance Biotherapeutics, Inc. (IOVA) Dfourth fifth; percentile 69.5 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $6.0B; last close $13.33 Warnings: dilution, short runway; 7 of 14 inputs | D | 69.5 | $6.0B | +276% | dilution, short runway |
| 259 | Scienture Holdings, Inc. (SCNX) Scienture Holdings, Inc. (SCNX) Dfourth fifth; percentile 69.7 Nasdaq · Pharmaceutical Preparations market equity $158.5M; last close $3.85 Warnings: fortress balance sheet; 7 of 14 inputs | D | 69.7 | $158.5M | -54% | fortress balance sheet |
| 260 | Rockwell Medical, Inc. (RMTI) Rockwell Medical, Inc. (RMTI) Dfourth fifth; percentile 70.0 Nasdaq · Pharmaceutical Preparations market equity $32.3M; last close $8.25 No active warnings; 9 of 14 inputs | D | 70.0 | $32.3M | -31% | |
| 261 | Bioventus Inc. (BVS) Bioventus Inc. (BVS) Dfourth fifth; percentile 70.3 Nasdaq · Surgical & Medical Instruments & Apparatus last close $12.70 No active warnings; 7 of 14 inputs | D | 70.3 | +104% | ||
| 262 | Ovid Therapeutics Inc. (OVID) Ovid Therapeutics Inc. (OVID) Dfourth fifth; percentile 70.5 Nasdaq · Pharmaceutical Preparations market equity $457.0M; last close $2.33 Warnings: dilution, short runway; 7 of 14 inputs | D | 70.5 | $457.0M | +105% | dilution, short runway |
| 263 | uniQure N.V. (QURE) uniQure N.V. (QURE) Dfourth fifth; percentile 70.8 Nasdaq · Pharmaceutical Preparations market equity $1.4B; last close $22.52 Warnings: fortress balance sheet; 8 of 14 inputs | D | 70.8 | $1.4B | -17% | fortress balance sheet |
| 264 | Regeneron Pharmaceuticals, Inc. (REGN) Regeneron Pharmaceuticals, Inc. (REGN) Dfourth fifth; percentile 71.1 Nasdaq · Pharmaceutical Preparations last close $739.13 No active warnings; 7 of 14 inputs | D | 71.1 | +43% | ||
| 265 | AbCellera Biologics Inc. (ABCL) AbCellera Biologics Inc. (ABCL) Dfourth fifth; percentile 71.4 Nasdaq · Pharmaceutical Preparations market equity $3.7B; last close $12.02 No active warnings; 7 of 14 inputs | D | 71.4 | $3.7B | +128% | |
| 266 | Cumberland Pharmaceuticals Inc. (CPIX) Cumberland Pharmaceuticals Inc. (CPIX) Dfourth fifth; percentile 71.6 Nasdaq · Pharmaceutical Preparations market equity $104.6M; last close $7.07 No active warnings; 10 of 14 inputs | D | 71.6 | $104.6M | +172% | |
| 267 | Bausch & Lomb Corp. (BLCO) Bausch & Lomb Corp. (BLCO) Dfourth fifth; percentile 71.9 NYSE · Ophthalmic Goods market equity $6.1B; last close $17.15 No active warnings; 7 of 14 inputs | D | 71.9 | $6.1B | +16% | |
| 268 | Pennant Group, Inc. (PNTG) Pennant Group, Inc. (PNTG) Dfourth fifth; percentile 72.2 Nasdaq · Services-Health Services market equity $1.4B; last close $40.33 No active warnings; 7 of 14 inputs | D | 72.2 | $1.4B | +46% | |
| 269 | Bausch Health Companies Inc. (BHC) Bausch Health Companies Inc. (BHC) Dfourth fifth; percentile 72.4 NYSE · Pharmaceutical Preparations market equity $2.3B; last close $6.04 No active warnings; 9 of 14 inputs | D | 72.4 | $2.3B | -1% | |
| 270 | 3M Co. (MMM) 3M Co. (MMM) Dfourth fifth; percentile 72.7 NYSE · Surgical & Medical Instruments & Apparatus market equity $84.4B; last close $163.56 No active warnings; 10 of 14 inputs | D | 72.7 | $84.4B | +12% | |
| 271 | Elanco Animal Health Inc. (ELAN) Elanco Animal Health Inc. (ELAN) Dfourth fifth; percentile 73.0 NYSE · Pharmaceutical Preparations market equity $11.3B; last close $22.53 No active warnings; 8 of 14 inputs | D | 73.0 | $11.3B | +19% | |
| 272 | ICU Medical Inc/De (ICUI) ICU Medical Inc/De (ICUI) Dfourth fifth; percentile 73.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $3.9B; last close $157.16 No active warnings; 9 of 14 inputs | D | 73.2 | $3.9B | +44% | |
| 273 | Butterfly Network, Inc. (BFLY) Butterfly Network, Inc. (BFLY) Dfourth fifth; percentile 73.5 NYSE · X-Ray Apparatus & Tubes & Related Irradiation Apparatus last close $8.02 No active warnings; 7 of 14 inputs | D | 73.5 | +309% | ||
| 274 | Vir Biotechnology, Inc. (VIR) Vir Biotechnology, Inc. (VIR) Dfourth fifth; percentile 73.8 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $1.9B; last close $11.12 No active warnings; 9 of 14 inputs | D | 73.8 | $1.9B | +92% | |
| 275 | Viatris Inc. (VTRS) Viatris Inc. (VTRS) Dfourth fifth; percentile 74.1 Nasdaq · Pharmaceutical Preparations market equity $20.0B; last close $17.44 No active warnings; 10 of 14 inputs | D | 74.1 | $20.0B | +73% | |
| 276 | Precision Optics Corporation, Inc. (POCI) Precision Optics Corporation, Inc. (POCI) Dfourth fifth; percentile 74.3 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $51.2M; last close $4.59 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | D | 74.3 | $51.2M | -1% | dilution, fortress balance sheet |
| 277 | Retractable Technologies Inc. (RVP) Retractable Technologies Inc. (RVP) Dfourth fifth; percentile 74.6 NYSE · Surgical & Medical Instruments & Apparatus market equity $19.8M; last close $0.68 Warnings: fortress balance sheet; 8 of 14 inputs | D | 74.6 | $19.8M | -13% | fortress balance sheet |
| 278 | NutriBand Inc. (NTRB) NutriBand Inc. (NTRB) Dfourth fifth; percentile 75.0 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies last close $6.08 Warnings: fortress balance sheet; 7 of 14 inputs | D | 75.0 | -38% | fortress balance sheet | |
| 279 | NutriBand Inc. (NTRBW) NutriBand Inc. (NTRBW) Dfourth fifth; percentile 75.0 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies last close $0.92 Warnings: fortress balance sheet; 7 of 14 inputs | D | 75.0 | -74% | fortress balance sheet | |
| 280 | Teleflex Inc. (TFX) Teleflex Inc. (TFX) Dfourth fifth; percentile 75.4 NYSE · Surgical & Medical Instruments & Apparatus market equity $5.3B; last close $124.12 No active warnings; 10 of 14 inputs | D | 75.4 | $5.3B | +17% | |
| 281 | Standard Biotools Inc. (LAB) Standard Biotools Inc. (LAB) Dfourth fifth; percentile 75.7 Nasdaq · Pharmaceutical Preparations market equity $263.1M; last close $0.67 Warnings: late filer, fortress balance sheet; 7 of 14 inputs | D | 75.7 | $263.1M | -49% | late filer, fortress balance sheet |
| 282 | Abeona Therapeutics Inc. (ABEO) Abeona Therapeutics Inc. (ABEO) Dfourth fifth; percentile 75.9 Nasdaq · Pharmaceutical Preparations market equity $283.6M; last close $4.95 Warnings: fortress balance sheet; 9 of 14 inputs | D | 75.9 | $283.6M | +11% | fortress balance sheet |
| 283 | Cytosorbents Corp. (CTSO) Cytosorbents Corp. (CTSO) Dfourth fifth; percentile 76.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $234.4M; last close $3.80 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | D | 76.2 | $234.4M | +630% | short runway, fortress balance sheet |
| 284 | Tilray Brands, Inc. (TLRY) Tilray Brands, Inc. (TLRY) Dfourth fifth; percentile 76.5 Nasdaq · Medicinal Chemicals & Botanical Products market equity $530.6M; last close $3.59 Warnings: fortress balance sheet; 8 of 14 inputs | D | 76.5 | $530.6M | -74% | fortress balance sheet |
| 285 | Baxter International Inc. (BAX) Baxter International Inc. (BAX) Dfourth fifth; percentile 76.8 NYSE · Surgical & Medical Instruments & Apparatus market equity $12.4B; last close $23.91 No active warnings; 11 of 14 inputs | D | 76.8 | $12.4B | +14% | |
| 286 | Vivos Therapeutics, Inc. (VVOS) Vivos Therapeutics, Inc. (VVOS) Dfourth fifth; percentile 77.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $3.0M; last close $0.15 Warnings: dilution, short runway, late filer; 9 of 14 inputs | D | 77.0 | $3.0M | -94% | dilution, short runway, late filer |
| 287 | Quest Diagnostics Inc. (DGX) Quest Diagnostics Inc. (DGX) Dfourth fifth; percentile 77.3 NYSE · Services-Medical Laboratories market equity $25.5B; last close $230.78 No active warnings; 11 of 14 inputs | D | 77.3 | $25.5B | +28% | |
| 288 | biote Corp. (BTMD) biote Corp. (BTMD) D/Eon the D/E boundary; percentile 77.6 Nasdaq · Medicinal Chemicals & Botanical Products market equity $68.1M; last close $1.17 No active warnings; 7 of 14 inputs | D/E | 77.6 | $68.1M | -45% | |
| 289 | Protalix BioTherapeutics, Inc. (PLX) Protalix BioTherapeutics, Inc. (PLX) D/Eon the D/E boundary; percentile 77.8 NYSE · Biological Products, (No Diagnostic Substances) market equity $217.5M; last close $2.69 No active warnings; 8 of 14 inputs | D/E | 77.8 | $217.5M | +16% | |
| 290 | Femasys Inc. (FEMY) Femasys Inc. (FEMY) D/Eon the D/E boundary; percentile 78.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $17.1M; last close $2.07 Warnings: dilution, short runway; 8 of 14 inputs | D/E | 78.1 | $17.1M | -51% | dilution, short runway |
| 291 | X4 Pharmaceuticals, Inc. (XFOR) X4 Pharmaceuticals, Inc. (XFOR) D/Eon the D/E boundary; percentile 78.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $276.6M; last close $2.79 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | D/E | 78.4 | $276.6M | +18% | dilution, fortress balance sheet |
| 292 | Milestone Scientific Inc. (MLSS) Milestone Scientific Inc. (MLSS) D/Eon the D/E boundary; percentile 78.6 NYSE · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $31.9M; last close $0.35 Warnings: late filer; 8 of 14 inputs | D/E | 78.6 | $31.9M | +5% | late filer |
| 293 | Gilead Sciences, Inc. (GILD) Gilead Sciences, Inc. (GILD) D/Eon the D/E boundary; percentile 78.9 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $182.4B; last close $147.07 No active warnings; 9 of 14 inputs | D/E | 78.9 | $182.4B | +34% | |
| 294 | C4 Therapeutics, Inc. (CCCC) C4 Therapeutics, Inc. (CCCC) D/Eon the D/E boundary; percentile 79.2 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $350.6M; last close $2.85 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | D/E | 79.2 | $350.6M | +67% | dilution, fortress balance sheet |
| 295 | Whitehawk Therapeutics, Inc. (WHWK) Whitehawk Therapeutics, Inc. (WHWK) D/Eon the D/E boundary; percentile 79.5 Nasdaq · Pharmaceutical Preparations market equity $197.8M; last close $3.45 No active warnings; 8 of 14 inputs | D/E | 79.5 | $197.8M | +139% | |
| 296 | Ironwood Pharmaceuticals Inc. (IRWD) Ironwood Pharmaceuticals Inc. (IRWD) D/Eon the D/E boundary; percentile 79.7 Nasdaq · Pharmaceutical Preparations market equity $639.5M; last close $3.87 Warnings: late filer, fortress balance sheet; 7 of 14 inputs | D/E | 79.7 | $639.5M | +224% | late filer, fortress balance sheet |
| 297 | Champions Oncology, Inc. (CSBR) Champions Oncology, Inc. (CSBR) D/Eon the D/E boundary; percentile 80.0 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $69.3M; last close $4.90 No active warnings; 8 of 14 inputs | D/E | 80.0 | $69.3M | -23% | |
| 298 | Voyager Therapeutics, Inc. (VYGR) Voyager Therapeutics, Inc. (VYGR) D/Eon the D/E boundary; percentile 80.3 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $146.0M; last close $2.36 Warnings: short runway; 7 of 14 inputs | D/E | 80.3 | $146.0M | -26% | short runway |
| 299 | Lucid Diagnostics Inc. (LUCD) Lucid Diagnostics Inc. (LUCD) D/Eon the D/E boundary; percentile 80.5 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $132.1M; last close $0.65 Warnings: dilution; 7 of 14 inputs | D/E | 80.5 | $132.1M | -3% | dilution |
| 300 | Merck & Co., Inc. (MRK) Merck & Co., Inc. (MRK) D/Eon the D/E boundary; percentile 80.8 NYSE · Pharmaceutical Preparations market equity $351.3B; last close $142.42 No active warnings; 8 of 14 inputs | D/E | 80.8 | $351.3B | +79% | |
| 301 | Lexicon Pharmaceuticals, Inc. (LXRX) Lexicon Pharmaceuticals, Inc. (LXRX) D/Eon the D/E boundary; percentile 81.1 Nasdaq · Pharmaceutical Preparations market equity $783.1M; last close $1.75 Warnings: fortress balance sheet; 7 of 14 inputs | D/E | 81.1 | $783.1M | +67% | fortress balance sheet |
| 302 | Hyperfine, Inc. (HYPR) Hyperfine, Inc. (HYPR) D/Eon the D/E boundary; percentile 81.4 Nasdaq · Electromedical & Electrotherapeutic Apparatus last close $0.94 No active warnings; 7 of 14 inputs | D/E | 81.4 | -43% | ||
| 303 | Surgery Partners, Inc. (SGRY) Surgery Partners, Inc. (SGRY) D/Eon the D/E boundary; percentile 81.6 Nasdaq · Services-General Medical & Surgical Hospitals, NEC market equity $1.8B; last close $13.62 Warnings: late filer; 7 of 14 inputs | D/E | 81.6 | $1.8B | -36% | late filer |
| 304 | Personalis, Inc. (PSNL) Personalis, Inc. (PSNL) D/Eon the D/E boundary; percentile 81.9 Nasdaq · Services-Medical Laboratories market equity $1.7B; last close $16.05 No active warnings; 10 of 14 inputs | D/E | 81.9 | $1.7B | +157% | |
| 305 | Accuray Inc. (ARAY) Accuray Inc. (ARAY) D/Eon the D/E boundary; percentile 82.2 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $28.8M; last close $0.24 Warnings: late filer; 7 of 14 inputs | D/E | 82.2 | $28.8M | -84% | late filer |
| 306 | Moderna, Inc. (MRNA) Moderna, Inc. (MRNA) D/Eon the D/E boundary; percentile 82.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $78.6B; last close $197.00 No active warnings; 8 of 14 inputs | D/E | 82.4 | $78.6B | +443% | |
| 307 | Stereotaxis, Inc. (STXS) Stereotaxis, Inc. (STXS) Eweakest fifth; percentile 82.7 NYSE · Electromedical & Electrotherapeutic Apparatus market equity $111.2M; last close $1.11 No active warnings; 9 of 14 inputs | E | 82.7 | $111.2M | -54% | |
| 308 | SkinHealth Systems Inc. (SKIN) SkinHealth Systems Inc. (SKIN) Eweakest fifth; percentile 83.0 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $74.0M; last close $0.57 No active warnings; 8 of 14 inputs | E | 83.0 | $74.0M | -66% | |
| 309 | Karyopharm Therapeutics Inc. (KPTI) Karyopharm Therapeutics Inc. (KPTI) Eweakest fifth; percentile 83.2 Nasdaq · Pharmaceutical Preparations market equity $13.6M; last close $0.60 Warnings: dilution, distress, fortress balance sheet; 7 of 14 inputs | E | 83.2 | $13.6M | -69% | dilution, distress, fortress balance sheet |
| 310 | Novavax Inc. (NVAX) Novavax Inc. (NVAX) Eweakest fifth; percentile 83.5 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $1.8B; last close $11.00 No active warnings; 8 of 14 inputs | E | 83.5 | $1.8B | +8% | |
| 311 | Pyxis Oncology, Inc. (PYXS) Pyxis Oncology, Inc. (PYXS) Eweakest fifth; percentile 83.8 Nasdaq · Pharmaceutical Preparations market equity $166.0M; last close $1.99 Warnings: short runway, distress; 7 of 14 inputs | E | 83.8 | $166.0M | +46% | short runway, distress |
| 312 | Opko Health, Inc. (OPK) Opko Health, Inc. (OPK) Eweakest fifth; percentile 84.1 Nasdaq · Pharmaceutical Preparations market equity $1.0B; last close $1.36 Warnings: fortress balance sheet; 8 of 14 inputs | E | 84.1 | $1.0B | -5% | fortress balance sheet |
| 313 | Amarin Corp. Plc\Uk (AMRN) Amarin Corp. Plc\Uk (AMRN) Eweakest fifth; percentile 84.3 Nasdaq · Pharmaceutical Preparations market equity $5.0B; last close $12.02 Warnings: fortress balance sheet; 8 of 14 inputs | E | 84.3 | $5.0B | -15% | fortress balance sheet |
| 314 | Kalaris Therapeutics, Inc. (KLRS) Kalaris Therapeutics, Inc. (KLRS) Eweakest fifth; percentile 84.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $59.5M; last close $2.50 Warnings: dilution; 7 of 14 inputs | E | 84.6 | $59.5M | -30% | dilution |
| 315 | Journey Medical Corp. (DERM) Journey Medical Corp. (DERM) Eweakest fifth; percentile 84.9 Nasdaq · Pharmaceutical Preparations market equity $68.8M; last close $5.95 No active warnings; 7 of 14 inputs | E | 84.9 | $68.8M | +4% | |
| 316 | Amgen Inc. (AMGN) Amgen Inc. (AMGN) Eweakest fifth; percentile 85.1 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $220.3B; last close $407.41 No active warnings; 11 of 14 inputs | E | 85.1 | $220.3B | +57% | |
| 317 | Organon & Co. (OGN) Organon & Co. (OGN) Eweakest fifth; percentile 85.4 NYSE · Pharmaceutical Preparations market equity $3.6B; last close $13.76 No active warnings; 8 of 14 inputs | E | 85.4 | $3.6B | +30% | |
| 318 | Sonoma Pharmaceuticals, Inc. (SNOA) Sonoma Pharmaceuticals, Inc. (SNOA) Eweakest fifth; percentile 85.7 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $5.6M; last close $1.17 Warnings: dilution, fortress balance sheet; 8 of 14 inputs | E | 85.7 | $5.6M | -67% | dilution, fortress balance sheet |
| 319 | Outset Medical, Inc. (OM) Outset Medical, Inc. (OM) Eweakest fifth; percentile 85.9 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $76.9M; last close $4.08 Warnings: dilution; 10 of 14 inputs | E | 85.9 | $76.9M | -73% | dilution |
| 320 | National Vision Holdings, Inc. (EYE) National Vision Holdings, Inc. (EYE) Eweakest fifth; percentile 86.2 Nasdaq · Ophthalmic Goods market equity $1.3B; last close $16.72 No active warnings; 7 of 14 inputs | E | 86.2 | $1.3B | -41% | |
| 321 | Natural Alternatives International Inc. (NAII) Natural Alternatives International Inc. (NAII) Eweakest fifth; percentile 86.5 Nasdaq · Medicinal Chemicals & Botanical Products market equity $25.3M; last close $1.17 Warnings: dilution, late filer, fortress balance sheet; 8 of 14 inputs | E | 86.5 | $25.3M | -26% | dilution, late filer, fortress balance sheet |
| 322 | DarioHealth Corp. (DRIO) DarioHealth Corp. (DRIO) Eweakest fifth; percentile 86.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $53.2M; last close $5.61 Warnings: dilution, short runway; 7 of 14 inputs | E | 86.8 | $53.2M | -58% | dilution, short runway |
| 323 | Intellia Therapeutics, Inc. (NTLA) Intellia Therapeutics, Inc. (NTLA) Eweakest fifth; percentile 87.0 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $1.8B; last close $12.59 Warnings: short runway; 7 of 14 inputs | E | 87.0 | $1.8B | -26% | short runway |
| 324 | Heron Therapeutics, Inc. (HRTX) Heron Therapeutics, Inc. (HRTX) Eweakest fifth; percentile 87.3 Nasdaq · Pharmaceutical Preparations market equity $68.0M; last close $0.36 Warnings: distress; 9 of 14 inputs | E | 87.3 | $68.0M | -75% | distress |
| 325 | Lexaria Bioscience Corp. (LEXX) Lexaria Bioscience Corp. (LEXX) Eweakest fifth; percentile 87.6 Nasdaq · Pharmaceutical Preparations market equity $5.3M; last close $3.37 Warnings: dilution, short runway, distress; 9 of 14 inputs | E | 87.6 | $5.3M | -21% | dilution, short runway, distress |
| 326 | Intelligent BIO Solutions Inc. (INBS) Intelligent BIO Solutions Inc. (INBS) Eweakest fifth; percentile 87.8 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $4.8M; last close $1.56 Warnings: dilution, short runway; 7 of 14 inputs | E | 87.8 | $4.8M | -76% | dilution, short runway |
| 327 | Bristol Myers Squibb Co. (BMY) Bristol Myers Squibb Co. (BMY) Eweakest fifth; percentile 88.2 NYSE · Pharmaceutical Preparations last close $59.56 No active warnings; 7 of 14 inputs | E | 88.2 | +55% | ||
| 328 | Bristol Myers Squibb Co. (CELG-RI) Bristol Myers Squibb Co. (CELG-RI) Eweakest fifth; percentile 88.2 NYSE · Pharmaceutical Preparations No active warnings; 7 of 14 inputs | E | 88.2 | n/a | ||
| 329 | Maravai Lifesciences Holdings, Inc. (MRVI) Maravai Lifesciences Holdings, Inc. (MRVI) Eweakest fifth; percentile 88.6 Nasdaq · Pharmaceutical Preparations last close $7.20 Warnings: late filer; 7 of 14 inputs | E | 88.6 | +166% | late filer | |
| 330 | Insight Molecular Diagnostics Inc. (IMDX) Insight Molecular Diagnostics Inc. (IMDX) Eweakest fifth; percentile 88.9 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $107.3M; last close $3.27 Warnings: fortress balance sheet; 8 of 14 inputs | E | 88.9 | $107.3M | +18% | fortress balance sheet |
| 331 | Nuwellis, Inc. (NUWE) Nuwellis, Inc. (NUWE) Eweakest fifth; percentile 89.2 Nasdaq · Electromedical & Electrotherapeutic Apparatus market equity $2.5M; last close $0.68 Warnings: dilution, short runway, fortress balance sheet; 8 of 14 inputs | E | 89.2 | $2.5M | -99% | dilution, short runway, fortress balance sheet |
| 332 | Aclaris Therapeutics, Inc. (ACRS) Aclaris Therapeutics, Inc. (ACRS) Eweakest fifth; percentile 89.5 Nasdaq · Pharmaceutical Preparations market equity $557.9M; last close $3.79 Warnings: short runway, fortress balance sheet; 9 of 14 inputs | E | 89.5 | $557.9M | +218% | short runway, fortress balance sheet |
| 333 | Brookdale Senior Living Inc. (BKD) Brookdale Senior Living Inc. (BKD) Eweakest fifth; percentile 89.7 NYSE · Services-Nursing & Personal Care Facilities market equity $2.6B; last close $10.88 No active warnings; 12 of 14 inputs | E | 89.7 | $2.6B | +39% | |
| 334 | Lifeward Ltd. (LFWD) Lifeward Ltd. (LFWD) Eweakest fifth; percentile 90.0 Nasdaq · Orthopedic, Prosthetic & Surgical Appliances & Supplies market equity $18.2M; last close $7.02 Warnings: dilution, late filer; 8 of 14 inputs | E | 90.0 | $18.2M | -10% | dilution, late filer |
| 335 | Canopy Growth Corp. (CGC) Canopy Growth Corp. (CGC) Eweakest fifth; percentile 90.3 Nasdaq · Medicinal Chemicals & Botanical Products market equity $358.2M; last close $0.85 Warnings: dilution, fortress balance sheet; 9 of 14 inputs | E | 90.3 | $358.2M | -32% | dilution, fortress balance sheet |
| 336 | Aytu Biopharma, Inc. (AYTU) Aytu Biopharma, Inc. (AYTU) Eweakest fifth; percentile 90.5 Nasdaq · Pharmaceutical Preparations market equity $22.3M; last close $2.10 Warnings: fortress balance sheet; 7 of 14 inputs | E | 90.5 | $22.3M | +22% | fortress balance sheet |
| 337 | Q32 Bio Inc. (QTTB) Q32 Bio Inc. (QTTB) Eweakest fifth; percentile 90.8 Nasdaq · Pharmaceutical Preparations market equity $240.8M; last close $8.11 No active warnings; 7 of 14 inputs | E | 90.8 | $240.8M | +651% | |
| 338 | Editas Medicine, Inc. (EDIT) Editas Medicine, Inc. (EDIT) Eweakest fifth; percentile 91.1 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $436.2M; last close $2.83 Warnings: fortress balance sheet; 7 of 14 inputs | E | 91.1 | $436.2M | -12% | fortress balance sheet |
| 339 | Dyadic International Inc. (DYAI) Dyadic International Inc. (DYAI) Eweakest fifth; percentile 91.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $16.2M; last close $0.49 Warnings: short runway, distress; 9 of 14 inputs | E | 91.4 | $16.2M | -53% | short runway, distress |
| 340 | Century Therapeutics, Inc. (IPSC) Century Therapeutics, Inc. (IPSC) Eweakest fifth; percentile 91.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $264.4M; last close $1.46 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | E | 91.6 | $264.4M | +312% | dilution, fortress balance sheet |
| 341 | Beyond Air, Inc. (XAIR) Beyond Air, Inc. (XAIR) Eweakest fifth; percentile 91.9 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $2.2M; last close $2.36 Warnings: dilution, short runway, distress; 7 of 14 inputs | E | 91.9 | $2.2M | -91% | dilution, short runway, distress |
| 342 | Precision Biosciences Inc. (DTIL) Precision Biosciences Inc. (DTIL) Eweakest fifth; percentile 92.2 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $177.5M; last close $6.43 Warnings: dilution, fortress balance sheet; 7 of 14 inputs | E | 92.2 | $177.5M | +38% | dilution, fortress balance sheet |
| 343 | Elutia Inc. (ELUT) Elutia Inc. (ELUT) Eweakest fifth; percentile 92.4 Nasdaq · Biological Products, (No Diagnostic Substances) last close $0.81 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | E | 92.4 | -3% | short runway, fortress balance sheet | |
| 344 | Airsculpt Technologies, Inc. (AIRS) Airsculpt Technologies, Inc. (AIRS) Eweakest fifth; percentile 92.7 Nasdaq · Services-Offices & Clinics of Doctors of Medicine market equity $119.3M; last close $1.66 Warnings: late filer; 9 of 14 inputs | E | 92.7 | $119.3M | -69% | late filer |
| 345 | Sutro Biopharma, Inc. (STRO) Sutro Biopharma, Inc. (STRO) Eweakest fifth; percentile 93.0 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $254.0M; last close $15.34 Warnings: dilution, short runway, distress, fortress balance sheet; 7 of 14 inputs | E | 93.0 | $254.0M | +133% | dilution, short runway, distress, fortress balance sheet |
| 346 | China Pharma Holdings, Inc. (CPHI) China Pharma Holdings, Inc. (CPHI) Eweakest fifth; percentile 93.2 NYSE · Pharmaceutical Preparations market equity $41.3M; last close $0.97 Warnings: dilution, late filer; 8 of 14 inputs | E | 93.2 | $41.3M | -55% | dilution, late filer |
| 347 | Fortress Biotech, Inc. (FBIO) Fortress Biotech, Inc. (FBIO) Eweakest fifth; percentile 93.6 Nasdaq · Pharmaceutical Preparations last close $2.10 Warnings: fortress balance sheet; 8 of 14 inputs | E | 93.6 | -26% | fortress balance sheet | |
| 348 | Fortress Biotech, Inc. (FBIOP) Fortress Biotech, Inc. (FBIOP) Eweakest fifth; percentile 93.6 Nasdaq · Pharmaceutical Preparations last close $17.95 Warnings: fortress balance sheet; 8 of 14 inputs | E | 93.6 | +104% | fortress balance sheet | |
| 349 | Co-Diagnostics, Inc. (CODX) Co-Diagnostics, Inc. (CODX) Eweakest fifth; percentile 94.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $6.8M; last close $1.10 Warnings: dilution, short runway, fortress balance sheet; 8 of 14 inputs | E | 94.1 | $6.8M | -88% | dilution, short runway, fortress balance sheet |
| 350 | Kyntra BIO, Inc. (KYNB) Kyntra BIO, Inc. (KYNB) Eweakest fifth; percentile 94.3 Nasdaq · Pharmaceutical Preparations market equity $24.1M; last close $5.83 No active warnings; 10 of 14 inputs | E | 94.3 | $24.1M | -36% | |
| 351 | Celularity Inc. (CELU) Celularity Inc. (CELU) Eweakest fifth; percentile 94.6 Nasdaq · Pharmaceutical Preparations market equity $47.4M; last close $1.48 Warnings: short runway, late filer; 8 of 14 inputs | E | 94.6 | $47.4M | -11% | short runway, late filer |
| 352 | Silo Pharma, Inc. (SILO) Silo Pharma, Inc. (SILO) Eweakest fifth; percentile 94.9 Nasdaq · Pharmaceutical Preparations market equity $2.3M; last close $1.41 Warnings: dilution, degenerate inputs, distress; 7 of 14 inputs | E | 94.9 | $2.3M | -76% | dilution, degenerate inputs, distress |
| 353 | VivoSim Labs, Inc. (VIVS) VivoSim Labs, Inc. (VIVS) Eweakest fifth; percentile 95.1 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $2.6M; last close $0.18 Warnings: dilution, short runway, late filer; 7 of 14 inputs | E | 95.1 | $2.6M | -90% | dilution, short runway, late filer |
| 354 | ALX Oncology Holdings Inc. (ALXO) ALX Oncology Holdings Inc. (ALXO) Eweakest fifth; percentile 95.4 Nasdaq · Pharmaceutical Preparations market equity $163.2M; last close $1.18 Warnings: dilution, short runway, degenerate inputs, fortress balance sheet; 8 of 14 inputs | E | 95.4 | $163.2M | +5% | dilution, short runway, degenerate inputs, fortress balance sheet |
| 355 | Biomerica Inc. (BMRA) Biomerica Inc. (BMRA) Eweakest fifth; percentile 95.7 Nasdaq · In Vitro & In Vivo Diagnostic Substances market equity $8.7M; last close $1.87 Warnings: short runway; 7 of 14 inputs | E | 95.7 | $8.7M | -26% | short runway |
| 356 | Bolt Biotherapeutics, Inc. (BOLT) Bolt Biotherapeutics, Inc. (BOLT) Eweakest fifth; percentile 95.9 Nasdaq · Pharmaceutical Preparations market equity $7.0M; last close $3.61 Warnings: short runway, distress; 7 of 14 inputs | E | 95.9 | $7.0M | -25% | short runway, distress |
| 357 | Pfizer Inc. (PFE) Pfizer Inc. (PFE) Eweakest fifth; percentile 96.2 NYSE · Pharmaceutical Preparations market equity $158.6B; last close $27.83 No active warnings; 8 of 14 inputs | E | 96.2 | $158.6B | +20% | |
| 358 | Dare Bioscience, Inc. (DARE) Dare Bioscience, Inc. (DARE) Eweakest fifth; percentile 96.5 Nasdaq · Pharmaceutical Preparations market equity $11.8M; last close $0.76 Warnings: dilution; 7 of 14 inputs | E | 96.5 | $11.8M | -64% | dilution |
| 359 | Longeveron Inc. (LGVN) Longeveron Inc. (LGVN) Eweakest fifth; percentile 96.8 Nasdaq · Pharmaceutical Preparations last close $2.38 Warnings: short runway; 7 of 14 inputs | E | 96.8 | +820% | short runway | |
| 360 | Clene Inc. (CLNN) Clene Inc. (CLNN) Eweakest fifth; percentile 97.0 Nasdaq · Pharmaceutical Preparations market equity $49.9M; last close $3.88 Warnings: dilution, distress; 8 of 14 inputs | E | 97.0 | $49.9M | -29% | dilution, distress |
| 361 | Agenus Inc. (AGEN) Agenus Inc. (AGEN) Eweakest fifth; percentile 97.3 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $339.5M; last close $7.53 Warnings: dilution, short runway; 7 of 14 inputs | E | 97.3 | $339.5M | +98% | dilution, short runway |
| 362 | Nektar Therapeutics (NKTR) Nektar Therapeutics (NKTR) Eweakest fifth; percentile 97.6 Nasdaq · Pharmaceutical Preparations market equity $1.4B; last close $40.77 Warnings: dilution, short runway; 8 of 14 inputs | E | 97.6 | $1.4B | +25% | dilution, short runway |
| 363 | Vyome Holdings, Inc. (HIND) Vyome Holdings, Inc. (HIND) Eweakest fifth; percentile 97.8 Nasdaq · Pharmaceutical Preparations market equity $14.2M; last close $2.03 Warnings: dilution, late filer, fortress balance sheet; 8 of 14 inputs | E | 97.8 | $14.2M | -58% | dilution, late filer, fortress balance sheet |
| 364 | Sintx Technologies, Inc. (SINT) Sintx Technologies, Inc. (SINT) Eweakest fifth; percentile 98.1 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $14.1M; last close $2.11 Warnings: dilution, short runway; 8 of 14 inputs | E | 98.1 | $14.1M | -63% | dilution, short runway |
| 365 | Coherus Oncology, Inc. (CHRS) Coherus Oncology, Inc. (CHRS) Eweakest fifth; percentile 98.4 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $165.3M; last close $1.06 Warnings: dilution, short runway; 10 of 14 inputs | E | 98.4 | $165.3M | -18% | dilution, short runway |
| 366 | Alector, Inc. (ALEC) Alector, Inc. (ALEC) Eweakest fifth; percentile 98.6 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $225.5M; last close $2.02 Warnings: short runway, fortress balance sheet; 7 of 14 inputs | E | 98.6 | $225.5M | -24% | short runway, fortress balance sheet |
| 367 | Atara Biotherapeutics, Inc. (ATRA) Atara Biotherapeutics, Inc. (ATRA) Eweakest fifth; percentile 98.9 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $92.6M; last close $9.05 Warnings: dilution, short runway; 8 of 14 inputs | E | 98.9 | $92.6M | -38% | dilution, short runway |
| 368 | HCW Biologics Inc. (HCWB) HCW Biologics Inc. (HCWB) Eweakest fifth; percentile 99.2 Nasdaq · Pharmaceutical Preparations market equity $2.8M; last close $1.62 Warnings: dilution, short runway, late filer, degenerate inputs, fortress balance sheet; 8 of 14 inputs | E | 99.2 | $2.8M | -84% | dilution, short runway, late filer, degenerate inputs, fortress balance sheet |
| 369 | Inovio Pharmaceuticals, Inc. (INO) Inovio Pharmaceuticals, Inc. (INO) Eweakest fifth; percentile 99.5 Nasdaq · Pharmaceutical Preparations market equity $112.7M; last close $1.08 Warnings: dilution, short runway, degenerate inputs; 7 of 14 inputs | E | 99.5 | $112.7M | -46% | dilution, short runway, degenerate inputs |
| 370 | PAVmed Inc. (PAVM) PAVmed Inc. (PAVM) Eweakest fifth; percentile 99.7 Nasdaq · Surgical & Medical Instruments & Apparatus market equity $21.5M; last close $2.67 Warnings: dilution, short runway, degenerate inputs; 7 of 14 inputs | E | 99.7 | $21.5M | -60% | dilution, short runway, degenerate inputs |
| 371 | Curis Inc. (CRIS) Curis Inc. (CRIS) Eweakest fifth; percentile 100.0 Nasdaq · Biological Products, (No Diagnostic Substances) market equity $1.5M; last close $0.78 Warnings: dilution, short runway, distress; 7 of 14 inputs | E | 100.0 | $1.5M | -96% | dilution, short runway, distress |
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
.jpg){kind=link}
